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We have prepared this document, “Sublingual Immunotherapy: World Allergy Organization Position Paper 2013
Update”, according to the evidence-based criteria, revising and updating chapters of the originally published paper,
“Sublingual Immunotherapy: World Allergy Organization Position Paper 2009”, available at www.waojournal.org.
Namely, these comprise: “Mechanisms of sublingual immunotherapy;” “Clinical efficacy of sublingual immunotherapy” –
reporting all the data of all controlled trials published after 2009; “Safety of sublingual immunotherapy” – with the
recently published Grading System for adverse reactions; “Impact of sublingual immunotherapy on the natural history
of respiratory allergy” – with the relevant evidences published since 2009; “Efficacy of SLIT in children” – with detailed
analysis of all the studies; “Definition of SLIT patient selection” – reporting the criteria for eligibility to sublingual
immunotherapy; “The future of immunotherapy in the community care setting”; “Methodology of clinical
trials according to the current scientific and regulatory standards”; and “Guideline development: from
evidence-based medicine to patients' views” – including the evolution of the methods to make clinical
recommendations.
Additionally, we have added new chapters to cover a few emerging crucial topics: “Practical aspects of schedules and
dosages and counseling for adherence” – which is crucial in clinical practice for all treatments; “Perspectives and new
approaches” – including recombinant allergens, adjuvants, modified allergens, and the concept of validity of the single
products. Furthermore, “Raising public awareness about sublingual immunotherapy”, as a need for our patients, and
strategies to increase awareness of allergen immunotherapy (AIT) among patients, the medical community, all
healthcare stakeholders, and public opinion, are also reported in detail.
Keywords: Sublingual immunotherapy, Allergen-specific immunotherapy, Mechanisms of SLIT, Safety of SLIT,
Efficacy of SLIT, Clinical trials methodology in SLITForeword
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and immunological treatments to the European Medicines
Agency (EMA), but these therapies call for new methods
of research, strategies for development, evaluation, use
and pharmacovigilance.
The allergen products used for both the diagnosis and
treatment of allergic diseases require particular attention
among the immunological and biological therapeutic areas,
due to the increase in the prevalence and social relevance
of allergies as well as the regulatory actions being requested
by the Directive 2001/83/EC and the following amending
EC Directives.al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Allergen Products and to address the many issues that
need harmonizing, and the regulatory aspects of allergen
products in Europe, the EMA on February 28, 2013
called a workshop in London with the participation of
all stakeholders.
The WAO SLIT document presented in this issue of
the World Allergy Organization Journal, and the EAACI
“Task Force Report on Clinical Outcomes to be used in
studies of Allergen Products”, represent relevant contri-
butions to answer the recommendations emerging from
this workshop.
From our side, we are working on a document, to be
shared with all stakeholders, on possible pathways for fa-
cilitating marketing authorization of allergen products.
These might include:
▪ a wider utilization of collaborative trials, with the
advantage of using the same control group for studies
of comparable active products, a substantial
advantage for pediatric investigational plans;
▪ new facilitated pathways of marketing authorization
allowing a faster access for patients to
immunotherapy without affecting an evidence-
based risk/benefit ratio;
▪ new study designs for well-conducted post-
registration trials, which, with the help of registries,
will allow a progressive evaluation of efficacy and
safety of new products and a pharmacovigilance in
line with the new ad hoc law;
▪ adequate information technology to take full
advantage of a wider access to individual data of
registration trials.
The harmonization of regulatory aspects of allergen
products represents however a work still in progress, as
shown by the concordant position on efficacy but the
different end-points adopted as well by the different
safety considerations in the recent FDA Advisory Com-
mittee votes on two SLIT products already approved by
EMA and marketed in most European Countries.
Therefore, we expect that the regulatory bodies, scien-
tific societies, manufacturers of allergen products, and
allergy patients’ organizations will continue their joint
commitment with the common goal of providing world-
wide to the many millions of subjects suffering from al-
lergic diseases an early and harmonized access to safe
and effective products.
Chapter 1 Introduction and historical background
to sublingual immunotherapy
The update of chapter one consists of two figures. Figure 1
provides an overview of the history of the development of
the first position paper, which was published in 2009.The next figure displays the evidence base for sublin-
gual immunotherapy since the publication of the first
position paper (Figure 2).
Chapter 2 Allergen-specific immunotherapy
There were no changes indicated for this chapter, and re-
lated updated details were integrated into other chapters.
Chapter 3 Mechanisms of sublingual
immunotherapy
 Allergen immunotherapy provides an opportunity to
study antigen-specific tolerance in humans.
 Subcutaneous immunotherapy (SCIT) suppresses
allergic Th2-mediated inflammation and increases
antigen-specific IgG, probably by induction of
regulatory T cells (Tregs), immune deviation (Th2
to Th1), and/or apoptosis of effector memory
Th2 cells.
 The oral mucosa is a natural site of immune
tolerance (Langerhans cells, FcR1, IL-10, IDO
[indoleamine 2,3-dioxygenase]).
 Sublingual immunotherapy (SLIT) in optimal doses
is effective; SLIT has been shown to induce
long-term remission after discontinuation and may
prevent new sensitizations, features consistent with
the induction of tolerance.
 SLIT induces modest systemic changes consistent
with SCIT, but additional local mechanisms in the
oral mucosa and/or regional lymph nodes are likely
important.
 Sublingual immunotherapy is associated with
○ retention of allergen in sublingual mucosa for
several hours.
○ early increases in antigen-specific IgE and
blunting of seasonal IgE.
○ persistent increases in antigen-specific IgG4 and
IgE blocking activity that parallel long-term
clinical benefits of both SCIT and SLIT.
○ inhibition of eosinophils and reduction of
adhesion molecules in target organs.
○ an early (at 4-12 weeks) increase in peripheral
phenotypic Tregs and delayed (at 12 months)
immune deviation in favor of Th1 responses.
○ detection of CD25 + FOXP + phenotypic Treg
cells in the sublingual mucosa.
○ alterations in dendritic cell markers
(e.g., increases in expression of complement
component C1Q) that correlate with
clinical response to treatment and merit
further study.
 Biomarkers that are predictive of or surrogates for
the clinical response to immunotherapy are not
currently available for routine use.
Figure 1 The historical process leading to the WAO SLIT Position Paper 2009.
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patient selection for immunotherapy.
○ Serum IgG–associated functional blocking
activity and basophil activation tests merit
further study.
○ Studies of peripheral T cell and dendritic cell
signatures have yielded important information,
but these tests are currently impractical for
routine clinical use.Clinical evidence for disease modification and induction
of tolerance
Since 2009, Cochrane meta-analyses have confirmed the
efficacy and safety of SLIT for seasonal and perennialallergic rhinitis [1] and conjunctivitis [2]. Several large
‘definitive’ trials have now confirmed the efficacy and
safety for seasonal rhinitis in both children and adults.
Long-term benefits of SLIT for at least 1 [3] or 2 [4]
years following discontinuation of treatment have been
demonstrated in 2 large independent trials of immuno-
therapy with grass pollen allergen tablets in adults. These
studies provide evidence for long-term disease remission
and disease modification consistent with the induction of
antigen-specific tolerance. In parallel with these novel
clinical data, there have been advances in our under-
standing of the underlying mechanisms of SLIT that
may give rise to putative biomarkers to predict the clin-
ical response [5-8].
Figure 2 Highlights of the evidences in SLIT, from 2009 to 2013, the scientific basis for the updating of “Sublingual Immunotherapy:
World Allergy Organization Position Paper 2009”.
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The oral cavity is a naturally tolerogenic environment,
remaining noninflamed despite being exposed continu-
ously to multiple foreign proteins. The presence of Lang-
erhans cells and monocytes capable of producing IL-10
and TGF-β are major contributors to the maintenance of
tolerance (see Chapter 3 of the 2009 WAO position paper
[9]). A recent study [10] has shown that T cells isolated
from the human buccal mucosa, in contrast to those iso-
lated from skin, express TGF-β1, IL-10, interferon-γ and
IL-17, particularly in the vestibular region, and markedly
express toll-like receptor (TLR) 2 and TLR4. Another
study from the same group [11] confirmed that oral Lang-
erhans cells within fresh human oral mucosal biopsies are
capable of rapidly taking up Phl p 5 (within 5 minutes) in
a dose-dependent fashion, resulting in their attenuated
maturation and enhanced production of inhibitory cyto-
kines (IL-10 and TGF-β). Taken together with the paucity
of mast cells in the oral vestibule compared to the sub-
lingual region [12], these data raise the possibility thattargeting the vestibule with allergen vaccine with or with-
out adjuvant has the potential to induce enhanced im-
mune deviation or tolerance, possibly with a lower
potential for mast cell–related local side effects, although
this remains to be tested.
Palomares et al. [13] recently highlighted that the ton-
sils and surrounding lymphoid tissue are located in the
gateway of both the alimentary and respiratory tracts
and may be important for local induction of tolerance to
both food and inhalant allergens. Abundant FOXP3+
Treg cells were detected in lingual and palatine tonsils.
Tonsil-derived plasmacytoid dendritic cells (DCs) were
shown to have the ability to generate functional CD4+
CD25+ CD127– FOXP3+ Treg cells. Triggering of tonsil-
derived T cells with TLR4 or TLR8 agonists or the pro-
inflammatory cytokines IL-1β or IL-6 was able to break
allergen-specific T-cell tolerance through a mechanism
dependent on the adaptor molecule myeloid differenti-
ation primary response gene 88 (MyD88) [14]. In par-
ticular, myeloid DCs and stimuli that activate them
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whereas plasmacytoid DCs and stimuli that activate
them, such as TLR7 and TLR9 agonists, did not have
any effect. These human ex vivo data raise the possibility
that immunotherapy strategies that target tonsillar tis-
sue may enhance the induction of tolerance, but this re-
mains to be tested in the context of different strategies
of oral immunotherapy.
In a double-blind 18-month controlled trial of high-
dose grass pollen SLIT (20 mcg Phl p 5 daily), biopsies
of the sublingual mucosa demonstrated more CD3+
FOXP3+ and CD25+ FOXP3+ T cells in SLIT-treated pa-
tients than in placebo-treated patients, and some CD3+
FOXP3+ cells were shown with triple immunofluores-
cence to express IL-10, a direct illustration of the induc-
tion of local phenotypic Treg cells following successful
treatment [15].
Specific antibody levels
Studies of sublingual grass pollen immunotherapy in gen-
eral show an increase in serum allergen-specific IgG4 and
IgG, although the increase is not as great as that seen with
SCIT [16,17]. Transient early increases in allergen-specific
IgE have also been observed and are associated with
blunting of seasonal increases in IgE [4]. However, some
SLIT studies have not shown increases in IgG levels, par-
ticularly following house dust mite immunotherapy [18].
In a study of high-dose grass pollen SLIT, increases in
grass pollen–specific IgA2 as well as IgG and IgG4
occurred in parallel with local increases in sublingual
FOXP3+ Tregs [15]. These increases were accompanied by
increases in serum inhibitory activity for binding of
allergen-IgE complexes to B cells (IgE-FAB), a validated
surrogate of IgE-facilitated antigen presentation to T cells.
Furthermore, the long-term clinical benefit observed for
2 years following a 3-year course of grass pollen SLIT was
associated with persistent elevations in serum levels of
both allergen-specific IgG4 [3,4] and functional IgG-
associated inhibitory activity for IgE-FAB when compared
to the levels in placebo-treated patients [4].
Effector cells in the target organ
Eosinophils and inflammatory mediators are elevated in
nasal lavage fluid and nasal biopsies after nasal allergen
challenge and during seasonal pollen exposure [Chapter 3
of ref. 9]. Recent attempts have been made to standardize
the collection of cytokines, mediators, and antibodies in
fluid collected on filters and sponges applied directly to
the nasal mucosa after nasal challenge [19]. For example,
tryptase levels peak at 5 minutes, consistent with early
mast cell activation, whereas increases in eosinophil cat-
ionic protein (ECP), a marker of eosinophils and Th2 cy-
tokines (IL-4, IL-5, and IL-13), peak at 3 to 8 hours during
the late nasal response. Whether alterations in these localmediators, antibodies, and cytokines correlate with the
clinical response to immunotherapy remains to be tested.
Effector cells in the periphery
Basophil activation can be measured ex vivo by short-
term (1 h) allergen stimulation of freshly harvested
whole blood. Techniques include measurement of baso-
phil histamine release and expression of surface activa-
tion markers, including CD63 and CD203b. Inhibition of
basophil activation has been shown following SLIT with
a combined grass and mite extract [20]; however, an-
other study of grass pollen SLIT [21] found no changes
in basophil activation and no correlation with clinical re-
sponse to treatment.
T cells and dendritic cells
Studies of peripheral blood T cell phenotype, prolifera-
tion, and cytokine production following SLIT have given
variable results. This is in part due to the different aller-
gens, doses, and protocols employed for immunotherapy
and the varying methods of T cell purification, process-
ing, and storage, that are difficult to standardize in
multicenter studies. Evaluation of T cell phenotype and
function overall favor the induction of Tregs and/or im-
mune deviation in favor of Th1 cells. Thus, birch pollen
SLIT in one study resulted in the induction of CD25+
FOXP3+ T cells at 4 weeks [22]. CD25+ Tregs suppressed
antigen-stimulated CD25– T cell proliferation. This sup-
pression was reversible at 4 weeks but not at 12 months
by the addition of an anti-IL-10 antibody to the culture
medium. In a study of house dust mite SLIT, suppression
of antigen-stimulated purified CD4+ T cell proliferation
was reversible at 6 but not 12 months by treatment with
soluble TGF-β receptor [18]. These data support that
Tregs are induced early, followed by delayed immune de-
viation in favor of Th1 responses at 12 months. Several
other recent studies support these observations [23-27].
In a double-blind study [20] of daily SLIT with the
combination of house dust mite and timothy grass pollen
in dual-sensitized adults (n = 30), clinical improvement and
decreased nasal allergen sensitivity were accompanied by
an increase in allergen-stimulated CD4+ CD25+ CD127low
CD45RO+ Foxp3+ T cells with reduced DNA methylation
at CpG sites [20], implying that tolerance might result from
epigenetic modification of memory Treg cells at the Foxp3
locus. In contrast, a double-blind placebo-controlled study
of 4 months of grass pollen SLIT (n = 89) that examined T
cell phenotype and antigen-specific T cells [28] found
that clinical improvement was accompanied by only
minor changes in the proportions of CD4+ T cells
expressing markers for Th1 (CCR5+, CXCR3+), Th2
(CRTh2+, CCR4+), or Treg (CD25+, CD127–, Foxp3+). A
modest downregulation of IL-4 and IL-10 gene expres-
sion and IL-10 secretion (P < 0.001) and a decrease in
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cells did not correlate with clinical benefit. Class II-
tetramer analyses of antigen-specific T cells failed to
show any major impact on either numbers or polarization
of circulating CD4+ T cells specific for Phl p 1 or Phl p 5.
Further and more prolonged studies are required to con-
firm or exclude whether tetramer tracking of T cells is
valuable as a biomarker of early onset of SLIT efficacy.
Tetramer studies of antigen-specific cells are limited by
class II restriction and the need to identify relevant T cell
epitopes. For this reason, Wambre and colleagues have
used T cell surface/intracellular marker expression with or
without associated tetramer staining to characterize sub-
jects allergic to grass pollen and mites, with the aim of dis-
tinguishing antigen-specific T cells from bystander T cell
responses [29]. These and other studies [30] have identi-
fied CD154 (CD40 ligand) as a potentially useful T cell
marker for future immunotherapy studies.
Human effector and regulatory dendritic cells are
important in directing T cell differentiation, phenotype,
and function. Following a detailed evaluation in vitro of
human effector and regulatory dendritic cells from hu-
man monocytes cultured under deforming conditions,
candidate dendritic cell markers were evaluated at the
messenger RNA and protein levels before and after grass
pollen allergen tablet SLIT [31]. Complement compo-
nent 1 (C1Q) and Stabilin-1 (STAB1) were increased in
PBMCs from clinical responders in contrast to that seen
in nonresponders or placebo-treated patients. Further
evaluation of C1Q and STAB1 expression as candidate
biomarkers during large trials of sublingual allergen im-
munotherapy are justified.
Biomarkers of clinical response to immunotherapy
A useful biomarker is one that is either predictive of or
a surrogate for the clinical response to immunotherapy.
A predictive biomarker might aid in selecting patients
who will respond (or in excluding potential nonre-
sponders), whereas a surrogate biomarker might be ef-
fective in monitoring the clinical response to treatment.
Ideally, the biomarker should be practical, easy to meas-
ure, technically robust, generalizable, and have good
sensitivity and specificity. Skin prick testing and raised
serum allergen-specific IgE are essential predictive bio-
markers that clearly augment information obtained from
the history alone. Nonetheless, these tests produce both
false positive and false negative results. One study sug-
gested that the ratio of specific IgE to total IgE might re-
late to the response to immunotherapy [32], whereas an
earlier study suggested that the ratio of allergen-specific
IgG4 to IgG1 may be more informative [33]. These hy-
potheses deserve further evaluation. The advent of molecu-
lar diagnosis may enhance predictive value by identifying
IgE sensitivity to relevant major allergens [34], for exampleto Phl p 5 and Phl p 1 for grass allergy, rather than only
cross-reactive IgE to panallergens such as Phl p 4 or Phl p
12 [35]. When there is discordance between the history
and IgE testing, local provocation to the relevant target
organ (eye, nose, bronchi) could be helpful, as might the
presence of local IgE in nasal, lacrimal, or bronchoalveolar
lavage fluid, although whether provocation testing or local
IgE is predictive of response to immunotherapy has not
been tested.
Based on knowledge of the mechanisms of SLIT, it is
attractive to consider that alterations in peripheral T cell
or dendritic cell signatures [31] would be useful for moni-
toring responses, although the complexity of processing
and performing these assays makes them unlikely candi-
dates for routine clinical use. Basophil activation testing is
of potential value, although conflicting results have been
obtained with SLIT [20,21]. Basophil testing requires fresh
processing of whole blood and access to a flow cytometer
within hours. Collection of nasal fluid on sponges or ab-
sorbent filters with measurement of mediators and cyto-
kines has been validated in response to nasal provocation,
but not in the context of immunotherapy trials [19], al-
though studies are in progress.
Serum-based assays are feasible in the context of clin-
ical trials and are largely restricted to measurements of
antibodies (specific IgE, IgG, IgG4, and IgA) and func-
tional antibody assays, such as detection of serum inhibi-
tory activity for antigen-stimulated basophil activation
tests [36] and inhibitory activity for binding of IgE-
allergen complexes to B cells [37]. The latter has been
shown to persist for at least 2 to 3 years following sub-
lingual immunotherapy [3] and to correlate modestly
but more convincingly with clinical response than meas-
urement of serum immunoreactive IgG antibodies alone
[38]. At the present time, apart from the use of serum
allergen-specific IgE for patient selection [39], there are
no biomarkers that can be reliably recommended for
selection of individual patients in routine practice for
immunotherapy, nor for monitoring the response to
treatment. However, rapid advances in the molecular
diagnosis of individual allergen IgE sensitivities com-
bined with better information on the constituents of the
allergen extracts available for therapy provide an exciting
opportunity to relate this new knowledge to prediction
of response to immunotherapy [34].
Chapter 4. Clinical efficacy of sublingual
immunotherapy
▪ As of June 2013, there were 77 randomized,
double–blind, placebo-controlled (RDBPC) trials of
SLIT, of which 62 were conducted with grass or
house dust mite (HDM) extracts. The majority of
these studies were heterogeneous for allergen dose,
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efficacy of SLIT do refer to products which have
demonstrated efficacy in appropriate studies.
▪ Seventeen trials, of which one was totally negative,
were published after the previous WAO position paper.
▪ The literature suggests that, overall, SLIT is clinically
effective in rhinoconjunctivitis and asthma, although
differences exist among allergens.
▪ The available meta-analyses are in favor of SLIT
(rhinitis and conjunctivitis in adults; asthma and rhin-
itis in children), although the conclusions are limited
by the heterogeneity of the studies in term of doses,
duration, and patient selection.
▪ Clinical efficacy and dose dependency have been
demonstrated for rhinoconjuntivitis due to grass
pollen in adequately powered, well-designed RDBPCs.
▪ Some open, controlled trials suggested that the
clinical efficacy of SLIT is similar to that of injection
immunotherapy.
▪ Dose-finding trials and large studies with properly
defined outcomes and sample sizes are needed for the
other relevant individual allergens.
Double-blind, randomized, placebo-controlled trials
The previous World Allergy Organization (WAO) Position
Paper [9] included 60 RDBPCs trials conducted with SLIT.
From then through June 2013, 17 new RDBPC trials were
published in English [40-55] (Table 1), 8 with grass ex-
tracts, 5 with HDM, 1 with Alternaria, and 3 with ragweed.
Six studies were conducted in children [40,47-49,53,54],
and 1 in elderly patients [50]. The number of patients
enrolled ranged from about 30 to more than 700, and the
duration varied from 4 months to 3 years. Five studies en-
rolled more than 400 patients [40,44,51,52]. Dropouts and
patient dispositions were reported in all trials, and 11 trials
[40,42,44,46,50-55] declared a formal sample size calcula-
tion. All of the trials but one [53] demonstrated a signifi-
cant effect of SLIT, independent of the allergen considered.
The relative change versus placebo, when reported, ranged
between 20% and more than 35%.
Of note, the only totally negative trial published after
the previous WAO Position Paper [53] was conducted
in more than 200 children recruited in a primary care
setting. In this case, the authors hypothesized that the
amount of allergen given was too low to produce a clin-
ical benefit.
Of the mentioned trials, one was performed using the
Vienna challenge chamber [43] and demonstrated that
the effect of SLIT begins quite early (at 4 months). This
relatively early onset of the effect was confirmed in an-
other trial with natural allergen exposure [55]. One of
the trials [45] investigated only immunological parame-
ters and showed a significant effect in the active group
but not in the placebo group relative to baseline.Overall, there have now been 77 RDBPC trials investi-
gating SLIT (Figure 3): 39 with grasses, 23 with mite, 5
with Parietaria, and 10 with other allergens (ragweed,
cypress, cat, olive, birch, cedar). Of the 77 trials, 5 were to-
tally negative. Nonetheless, several trials consistently re-
ported efficacy to be dose dependent (for review see [56]),
reinforcing the robustness of the results so far reported in
clinical trials.
Meta-analyses
After the previous WAO position paper [9], 4 new
meta-analyses of SLIT for respiratory allergy were pub-
lished [2,57-59]. So far, the most comprehensive meta-
analysis of SLIT in allergic rhinitis is that by Radulovic
et al. [58], which included 22 trials and a total of 979 pa-
tients. The overall results favored SLIT over placebo for
rhinitis symptoms and medication scores. For symptoms,
the standardized mean difference (SMD) was –0.42 (95%
CI –0.69 to –0.15, P = 0.002). For medications, the SMD
was –0.43 (95% CI –0.63 to –0.23, P = 0.00003). However,
great heterogeneity remained (I2 between 40% and 95%,
depending on the outcome analyzed) due to the largely
different inclusion criteria, outcomes, doses, and durations
among the trials. In addition, this analysis did not include
the most recent large trials. However, the increasing num-
ber of available studies has enabled more detailed meta-
analyses, for instance according to the allergen or the
disease. One meta-analysis was limited to mite [59]. An-
other that considered only grass allergens [57] clearly
showed the superiority of SLIT over placebo for both
symptoms and medications. Finally, another meta-analysis
limited to conjunctivitis symptoms [2] confirmed a signifi-
cant difference in favor of SLIT, with an SMD of 0.41
(95% CI 0.28 to 0.53) and moderate heterogeneity (I2:
59%). The new meta-analyses substantially confirmed the
previous results, showing an overall efficacy of SLIT for
different outcomes. However, the great heterogeneity of
the results (due to the inherent heterogeneity of trials) still
limits the reliability of the results [60,61].
Comparison of the efficacy of SLIT and SCIT
The problem of comparing the efficacy of subcutaneous
immunotherapy (SCIT) and SLIT is still open. The com-
parison is technically difficult, because head-to-head
comparisons need a double-blind, double-dummy design,
with a careful choice of outcomes and dosages. Surpris-
ingly, given the technical difficulty, 3 comparative studies
[24,27,62] were carried out after the 2009 WAO position
paper [9], as summarized in Table 2. The study by Eifan
et al. [27] was randomized, open, and controlled and in-
volved 48 children monosensitized to mite. They received
SCIT, SLIT, or pharmacotherapy alone for 1 year. The 2
routes of immunotherapy did not differ in terms of clinical
efficacy, and both were superior to pharmacotherapy. The
Table 1 Randomized, double-blind, placebo-controlled trials of SLIT performed since 2009
Author, year
[reference]
Ages (y) A/P Dropouts
(A/P)
Allergen Duration Dose and
administration
Disease Manu-
facturer
Main positive results Negative results
Horak, 2009 [43] 18-50 45/44 3/4 Grass 4 mo 20 mcg RC STA Significant reduction in RC score
in Vienna challenge chamber at
4 mo in SLIT vs baseline and vs
placebo (the reduction vs
placebo was 29%)
Nasal airflow
Phl p 5/day Weight of secretions
Tablets Basophil activation
Increased IgE and IgG4
Skoner, 2010 [46] 18-50 39 med 4 Ragweed 6 mo 4.8 or 48 mcg RC GRE Combined symptoms+drugs and
drug score versus placebo
Nasal challenge, IgE
36 high 5 Amb a 1/day Symptom score
40 plac 3 Metered pump during peak season
Cortellini, 2010 [42] 16-44 15/12 0/1 Alternaria 10 mo 60 mcg Alt a 1 cumul.
6 mcg/mo
RCA ANA Significant reduction in
combined score (−38% versus
placebo).
Specifcic IgE and IgG4
Drops Significant reduction in skin
reactivity
Panizo, 2010 [45] 18-65 52/26 2/1 Grass 5 mo 25 mcg Phl p 5/day
Tablets
RC ALK Increase in IgE, IgG4, and IgE
blocking activity only in active
Yonekura, 2010 [48] 7-15 20/11 1/2 Mite 1 y 0.5 mcg Der f 1 once
a week
RC TOR Significant decrease in symptoms
and combined score in wk 0–3
and 37–40 only in SLIT
Medication score
Blaiss, 2011 [40] 5-17 349/358 33/30 Grass 6 mo 450 g Phl p 5/mo RC STA Significant reduction in
combined score (−26%) versus
placebo. Quality of Life 38%
improvement vs placebo
Asthma symptoms
Nelson, 2011 [44] 18-63 213/225 33/33 Grass 10 mo 450 mcg Phl p 5/mo
Tablets
RCA STA Significant reduction in
combined score (−20%and
medication score (−20%) versus
placebo
Daily medication score
Bush, 2011 [41] 18-50 High 10 2 Mite 18 mo 70 or 1 mcg RA GRE Significant reduction in specific
bronchial reactivity
Symptoms and medication
scores
Low 10 3 (Der f) Der f 1 per dose.
Pla 11 5 Drops Increase in IgG4
Stelmach, 2012 [47] 6-18 Cont 20 3 Grass 2 y Cumulative 7.3 and
3.6 mcg Phl p 5.
Drops
RCA ALK Significant improvement in
drugs +symptoms with both
continuous and precoseasonal
regimen. Reduction in FeNO
Symptom score
Prec 20 1 Medication score
Pla 20 2 Pulmonary function
de Bot, 2012 [53] 6-18 126/125 15/17 Mite 2 y 4.06 mcg RC ART Symptom score
Der p 1/week QoL
Drops Medication score
Well days
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Table 1 Randomized, double-blind, placebo-controlled trials of SLIT performed since 2009 (Continued)
Ahmadiasfshar
2012 [49]
5-18 12/12 2/2 Grass 6 mo Cumulative: about
6,000 IR Spray
RC STA Significant improvement in
symptom and medication scores
Reduction of skin wheal diameter
Wahn, 2012 [54] 4-12 158/49 26/2 Grass 8 mo Cumulative: 7.2–8.4
mg group 5
RC ALL Significant reduction versus
placebo in combined symptom/
medication and individual scores
Drops
Cox, 2012 [51] 18-65 233/240 26/17 Grass 6 mo Cumulative: approx
3.6 mg group 5
allergen.
RC STA Significant reduction of
combined symptom +
medication score (−28% versus
placebo) and overall quality
of life
Itchy nose symptom score
versus placebo
Tablets
Bozek, 2013 [50] 60-75 51/57 7/9 Mite 3 y NS RC STA Total nasal scores decreased by
44% from baseline in SLIT and by
6% in placebo.
Symptoms after specific nasal
provocation versus placebo
Medication score decreased 35%
from baseline in SLIT group.
Wang, 2013 [55] 4-65 60/60 12/23 Mite 6 mo NS RC ZHE Significant decrease in each
individual rhinitis symptom
versus placebo starting from
week 14.
No change versus placebo in
medication intake
Nolte, 2013 [18] 18-50 High 187 142 Ragweed 1 y 6 or 12 mcg RCA MSD Significant decrease in combined
symptom + medication score for
both active groups VS placebo
(21% and 27%)
Low 190 overall Amb a 1 daily
Pla 188 Tablets
Creticos, 2013 [52] 18-50 Low 197 40 Ragweed 1 y Cumulative dose RCA MSD Only the high dose decreased
daily symptom, medication, and
combined scores during peak
pollen season and whole season
versus placebo.
Low dose overall less effective
than the 2 other doses on
symptoms/medications in peak
pollen and whole season
Med 195 43 4.38 mg Amb a 1
High 194 57 Tablets
Pla 198 38
Abbreviations: A/P active/placebo, NS not stated, RC rhinoconjunctivitis, RCA rhinoconjuntivitis/asthma, STA Stallergenes, GRE Greer, ANA Anallergo, ALL Allergopharma, ALK ALK-Abellò, MSD Merck Sharp and Dome,
TOR Torii Pharmaceuticals, ZHE Zheng Wolwo Bio Pharma.
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Figure 3 Number of double-blind, placebo-controlled trials
investigating SLIT up to June 2013.
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parallel-group trial to assess the efficacy and feasibility of
SCIT induction followed by SLIT maintenance. The 2
single routes were also compared. The combined regi-
men did better than the 2 taken separately, with a slight
advantage for SCIT alone over SLIT alone on some out-
comes. The third study [62] was again a double-dummy
study versus placebo in which both treatments achieved
a significant clinical improvement versus baseline, with
SCIT doing on average better than SLIT in the direct
comparison.
Non-RDBPC trials
Additional open, randomized, controlled clinical trials
were performed after the publication of the previousTable 2 Direct comparisons of SLIT and SCIT for efficacy
Author, year design Ages (y) Treat-ment Dropouts Allergen Dur
Eifan, 2010 [27] 5–12 16 SCIT 2 Mite 1 y
Randomized,
open, controlled
16 SLIT 1
16 CON 2
Keles, 2011 [24] 5–12 15 SCIT 2 Mite 18 m
Double blind, double
dummy, controlled
15 SLIT 2
15 SLIT 1
+ SCIT
15 CON 3
Yukselen, 2012 [62] 7–14 10 SCIT 1 Mite 1 y
10 SLIT 1Double blind, double
dummy, placebo
controlled 10 PLA 0
Abbreviations: CON control, PLA placebo, SCIT subcutaneous immunotherapy, SLIT s
analog scale.WAO position paper [9]. These studies, despite their
methodological limitations, provided some interesting
insights into the efficacy of SLIT. One study compared
coseasonal and continuous regimens in children suffer-
ing from grass allergy [63]. In this study, the continuous
(all year long) regimen started in the preseason. The
main results were that in the first pollen season the con-
tinuous regimen performed better on symptoms, but
starting from the second season, the 2 regimens became
more and more similar, so that at the third season no
difference could be detected. Another study was con-
ducted in a randomized single-blind fashion for 3 years
with an Alternaria extract [64]. There was a progressive
reduction in symptoms, as measured with a visual analog
scale, which became significant after the first year in the
active group. Only few mild adverse events were re-
ported. Another open randomized trial in adults (33
patients) showed that a preseasonal regimen was equiva-
lent in efficacy, as measured by visual analog scale, to
the continuous administration [65]. These results are
further reinforced by those of a previous RDBPC trial
comparing precoseasonal and continuous regimens in
children [47]. A study in the United States [66] com-
pared the efficacy of HDM SLIT in 134 monosensitized
or polysensitized patients. After 1 year, symptoms and
drug scores decreased significantly in both groups, but
no difference between groups was detected. The same
was observed in another trial comparing the quality of
life in patients receiving SLIT who were either mono- or
polysensitized, where no difference between the 2 groupsation Cumulative doses Disease Main results
SCIT 111 mg Der
p 1/156 mg Der f 1
RA Significant reduction of
total rhinitis and asthma
score, medication score,
VAS, and skin reactivity
P < 0.05 versus
pharmacotherapy for
both SCIT and SLIT. No
difference between
routes of administration.
SLIT 295.5 mg Der
p 1/f 1
o Der p 1: 53 mcg SLIT
and 42 mcg SCIT
A Decreased asthma attacks
and use of steroids at 4,
12, 18 mo for SCIT and
SCIT+SLIT, at 12 mo only
for SLIT. No change in
VAS for asthma with SCIT
or SIT alone.
173,733 TU (86,866.5
TU D pt. and 86,866.5
TU Df ).
RA Significant reduction in
symptom and medication
score versus baseline with
both treatments. SCIT
better than SLIT versus
placebo.
ublingual immunotheapy, RA Rhinitis with asthma, A asthma, VAS visual
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cluded that SLIT can also be effective in patients with
multiple sensitizations, provided that the clinically rele-
vant allergen is correctly identified [68].
Chapter 5: Safety of sublingual immunotherapy
 Sublingual immunotherapy (SLIT) appears to be
better tolerated than subcutaneous immunotherapy
(SCIT).
 SLIT should only be prescribed by physicians with
appropriate allergy training and expertise.
 Specific instructions should be provided to patients
regarding the management of adverse reactions,
unplanned interruptions in treatment, and situations
when SLIT should be withheld.
 The majority of SLIT adverse events are local
reactions (e.g., oromucosal pruritus) that occur
during the beginning of treatment and resolve
within a few days or weeks without any medical
intervention (e.g., dose adjustment, medication).
 A few cases of SLIT-related anaphylaxis have been
reported but there have been no fatalities.
 Risk factors for the occurrence of SLIT severe
adverse events (SAEs) have not yet been established,
although there is some suggestion that patients who
have had prior systemic reactions to SCIT may be at
increased risk.
 There is a need for a generally accepted system of
reporting allergen immunotherapy (AIT) adverse
reactions that is applicable to both clinical practice
and research.
○ A uniform classification system for grading for
AIT systemic reactions has been developed.
○ A classification system for grading SLIT local
reactions has also been developed.
○ Consistent use of the Systemic Reaction and
SLIT Local Reaction Grading Systems is
recommended.Classification and frequency of SLIT adverse events
One of the purported advantages of SLIT over SCIT is
greater safety, which allows for administration of this
treatment outside of the medical setting. In a compre-
hensive review of 104 articles on SLIT, there were 66
studies that provided some information on safety and
tolerance, representing 4378 patients who received ap-
proximately 1,181,000 SLIT doses [69]. Oromucosal re-
actions, considered a SLIT local reaction, were relatively
common, affecting up to 75% of patients, and were seen
most frequently in the build-up phase. In the studies
that specified the type of reaction, 169 (0.056%) of
314,959 doses administered were classified as producing
systemic reactions. To provide some perspective, in anAmerican Academy of Allergy Asthma & Immunology/
American College Of Allergy Asthma & Immunology
(AAAAI/ACAAI) 3-year immunotherapy safety surveil-
lance study, the incidence of reported SCIT systemic
reactions was 0.1% of injections, the majority of which
were classified as Grade 1 (cutaneous or upper respira-
tory symptoms) [70,71].
Since the publication of the first WAO SLIT Position
Paper [9], at least 5 large randomized double-blind
placebo-controlled (RDBPC) trials that included more
than 100 patients have been published [40,44,46,51,53].
In these trials, the overall occurrence of side effects did
not differ from the occurrence in previous studies, and
no new safety concerns were raised. Local side effects
(oral and gastrointestinal) continue to represent the ma-
jority (~80% to 90%) of all reported adverse reactions.
Long-term follow-up of some of the large trials indicated
that the number and intensity of AEs tend to decline
with additional courses of SLIT [3,72].
The amount of information provided about AEs varied
greatly in many of the earlier SLIT studies; some in-
cluded only general summary statements, such as “no
relevant side effects,” whereas others provided detailed
analyses of the AEs [69]. One consideration with SLIT is
that the majority of doses are administered outside of
the clinic setting with no direct medical supervision, and
the accuracy of the AE reporting depends on the pa-
tient’s and/or family’s recall and interpretation of the
event. The heterogeneity in classifying and reporting
SCIT and SLIT adverse reactions in clinical trials makes
comparisons and analysis of safety difficult. In recogni-
tion of the need for a uniform classification system for
AIT adverse reactions, an international Task Force com-
posed of members of the academic, clinical, and research
allergy communities was formed. Using existing grading
systems as a template, the Task Force combined infor-
mation from the members’ clinical experience and data
from published studies and safety surveys to develop a 5-
grade classification system for systemic AEs (the World
Allergy Organization Subcutaneous Immunotherapy Sys-
temic Reaction Grading System, Table 3) [73]. Although
the grading system was developed for SCIT, it also applies
to SLIT. The grade is based on the organ system(s) in-
volved and severity and is to be determined by the physi-
cian’s clinical judgment after the event is over.
Local side effects are the most frequent adverse reac-
tions associated with SLIT, and these local reactions can
be severe and/or bothersome enough to cause treatment
discontinuation. In the previously discussed review [69],
SLIT adverse reactions accounted for treatment with-
drawal in 3% of the SLIT patients, compared with 1.4%
of the placebo-treated patients. Local adverse reactions
are often the reason cited for treatment discontinuation
in both RDBPC and observational studies [69,74,75].
Table 3 World Allergy Organization subcutaneous systemic reaction grading system
Grade 1 Grade 2 Grade 3 Grade 4 Grade 5
Symptoms(s)/sign(s) of one
organ system present:*
Symptoms(s)/sign(s) of more
than one organ system present:
Lower respiratory Lower or upper respiratory Death
Asthma (eg, 40% PEF or FEV1
drop, NOT responding to an
inhaled bronchodilator)
Respiratory failure with or
without loss of consciousnessCutaneous
Generalized pruritis, urticaria,
flushing, or sensation of heat or
warmth**
or or or or
Angioedema (not laryngeal,
tongue, or uvular)
Lower respiratory Upper respiratory Cardiovascular
or Asthma: cough, wheezing,
shortness of breath (eg, <40%
PEF or FEV1 drop, responding
to an inhaled bronchodilator)
Laryngeal, uvula, or tongue
edema with or without stridor
Hypotension with or without loss
of consciousness
Upper respiratory
Rhinitis (eg, sneezing, rhinorrhea,
nasal pruritis, and/or nasal
congestion)
or or
Throat-clearing (itchy throat)
or Gastrointestinal
Cough perceived to come from
the upper airway, not the lung,
larynx, or trachea
Abdominal cramps, vomiting, or
diarrhea
or or
Conjunctival
Conjunctival erythema, pruritus,
or tearing
Other
Uterine cramps
Other
Nausea, metallic taste, or
headache
Patients may also have a feeling of impending doom, especially in grades 2, 3, or 4.
Note: children with anaphylaxis seldom convey a sense of impending doom and their behavior changes may be a sign of anaphylaxis, eg, becoming
very quiet or irritable and cranky.
Scoring includes a suffix that denotes if and when epinephrine is administered in relationship to symptom(s)/sign(s) of the SR: a, ≤5
minutes; b, >5 minutes to ≤10 minutes; c, >10 to ≤20 minutes; d, >20 minutes; z, epinephrine not administered.
The final grade of the reaction will not be determined until the event is over, regardless of the medication administered. The final report should
include the first symptom(s)/sign(s) and the time of onset after the subcutaneous allergen immunotherapy injection† and a suffix reflecting if and
when epinephrine was administered, eg, Grade 2a; rhinitis: 10 minutes.
Final report: Grade, a-d or z ________________First symptom ________________ Time of onset of first symptom ________________
Comments††
*Each Grade is based on organ system involved and severity. Organ systems are defined as: cutaneous, conjunctival, upper respiratory, lower respiratory,
gastrointestinal, cardiovascular, and other. A reaction from a single organ system such as cutaneous, conjunctival, or upper respiratory, but not asthma,
gastrointestinal, or cardiovascular is classified as a Grade 1. Symptom(s)/sign(s) from more than one organ system or asthma, gastrointestinal, or cardiovascular are
classified as Grades 2 or 3. Respiratory failure or hypotension, with or without loss of consciousness, defines Grade 4 and death Grade 5. The grade is determined
by the physician’s clinical judgment.
**This constellation of symptoms may rapidly progress to a more severe reaction.
†Symptoms occurring within the first minutes after the injection may be a sign of severe anaphylaxis. Mild symptoms may progress rapidly to severe anaphylaxis
and death.
††If signs or symptoms are not included in the Table or the differentiation between an systemic response and vasovagal (vasodepressor) reaction, which may
occur with any medical intervention, is difficult, please include comment, as appropriate.
Adapted from [73]. Reprinted with permission from Elsevier Publishers.
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events, a uniform system for grading the severity of local
AEs was perceived as necessary for uniform reporting and
classification of SLIT local adverse reactions. A WAOTask Force was formed for the purpose of developing a
classification system for grading SLIT local reactions [76].
The Task Force examined the clinical trials and the post-
marketing surveillance data, and considered the MedDRA
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clinically based 3-grade classification system for local SLIT
reactions (Table 5). This grading system is primarily based
on the patient’s subjective reporting, with a severe reaction
(Grade 3) being one that leads to treatment discontinu-
ation. Note that gastrointestinal symptoms associated with
SLIT can be classified as either local reactions, if only oro-
mucosal symptoms are present, or as a systemic reaction,
if occurring in conjunction with other systemic symptoms.
SLIT serious adverse events
In the SLIT comprehensive review [69], there were no fa-
talities or SLIT-related systemic reactions associated with
hypotension, although there were 14 probable SLIT-related
SAEs in 3984 patients treated with a total of 1,019,826
doses. This represents 1.4 SAEs per 100,000 SLIT doses.
The most common SLIT-related SAEs were asthmatic re-
actions (n = 7), one of which required hospitalization; the
others were abdominal pain/vomiting (n = 3), uvula edema
(n = 1), and urticaria lasting 48 hours. Subsequent to this
review, there have been a few case reports of systemic reac-
tions of a severity that should be categorized as anaphylaxis
(Table 6) [79-86]. In 2 case reports, 4 patients had expe-
rienced systemic reactions with prior SCIT treatment
[79,85]. Two of these 4 experienced anaphylaxis with
the first SLIT tablet [79].
Risk factors for SLIT adverse events
No clear predictors for SLIT AEs have been identified,
although some of the factors in the SLIT anaphylaxis
case reports are recognized as risk factors for SCIT:Table 4 Description of the local side effects related to SLIT (M
Local side effect MedDRA pre
Mouth/ear Altered taste perception Dysgeusia
Itching of lips Oral pruritus
Swelling of lips Lip swelling
Itching of the oral mucosa Oral pruritus
Swelling of the oral mucosa Oedema muc
Itching of the ears Ear pruritus
Swelling of the tongue Swollen tong
Glossodynia Glossodynia
Mouth ulcer Mouth ulcera
Tongue ulcer Tongue ulcer
Throat irritation Throat irritatio
Uvular edema Pharyngeal o
Nausea Nausea
Upper gastro-intestinal Stomach-ache Abdominal p
Vomiting Vomiting
Abdominal pain Abdominal p
Lower gastro-intestinal Diarrhea Diarrhoeaheight of season [81], history of previous systemic reac-
tions [79], dose [80], and accelerated schedules [83]. In
addition, most of the patients with SLIT-related SAEs or
anaphylaxis had asthma; symptomatic asthma has been
identified as a risk factor for AEs with SCIT [70,87].
The numbers have been too small to identify risk fac-
tors for SLIT SAEs. In 6 case reports of SLIT-associated
anaphylaxis [79-84], 5 of 6 patients were female, all were
adolescents or young adults, 5 of the 6 had a history of
asthma, and 2 had a previous history of severe reactions
to SCIT. In a study evaluating the safety of SLIT in 43
patients, 3 of the 5 patients who experienced a SLIT
systemic reaction had a history of a previous SCIT sys-
temic reaction [86]. Prior systemic reaction with SCIT
was identified as a possible risk factor in 4 patients in
case reports [79,85].
In general, patients receiving SLIT are not prescribed
injectable epinephrine in the event of a rare systemic re-
action. However, in the study of 43 patients that identi-
fied prior SCIT systemic reaction as a possible predictor
for SLIT systemic reaction, injectable epinephrine was
prescribed as an ethics committee requirement, and 2
patients used it [86]. The Federal Drug Administration
(FDA) has stipulated a similar requirement for prescrib-
ing epinephrine autoinjectors for the subjects participat-
ing in US SLIT clinical trials. In 2 of these studies, which
together included 345 children and 439 adults, a small
number of patients in the placebo (n = 2) and SLIT (n = 4)
groups used the epinephrine autoinjector [40,44]. In 3
instances, it was used for symptoms not caused by active
treatment. One patient in the placebo group used itedDRA 14.1) [78]
ferred term MedDRA CODE MedDRA low level term (LLT)
10013911 Taste alteration
10052894 Itching mouth
10024570 Swelling lips
10052894 Itching mouth
osal 10030111 Mucosal swelling
10052138 Ear pruritus
ue 10042727 Tongue swelling non-specific
10018388 Glossodynia
tion 10028034 Mouth ulcer
ation 10043991 Tongue ulceration
n 10043521 Throat irritation
edema 10034829 Pharyngeal oedema
10028813 Nausea
ain upper 10000087 Stomach ache
10047700 Vomiting
ain 10000081 Abdominal pain
10012735 Diarrhea
Table 5 WAO Grading system for SLIT local adverse events
Symptom/sign (see Table 1) Grade 1 – Mild Grade 2 – Moderate Grade 3 - Severe Unknown severity
Pruritus/swelling of mouth,
tongue or lip
Not troublesome Troublesome • Grade 2 The treatment is discontinued
but there is no subjective
and/or objective description
of the severity from the
patient/physician
Throat irritation AND OR AND
Nausea No symptomatic treatment
required
Requires symptomatic
treatment
• SLIT discontinued
because of local side
effects
Abdominal pain AND AND
Vomiting No discontinuation of SLIT
because of local side effects
No discontinuation of SLIT
because of local side effects
Diarrhea
Heartburn
Uvular oedema
Each local adverse event can be early (<30 minutes) or delayed
From [76]. Reprinted with permission from Elsevier.
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to exposure to a grassy field [40], and another placebo
patient used it in response to what was subsequently
deemed to be an anxiety attack. In the SLIT group, self-
administered epinephrine was used in 4 patients for symp-
toms diagnosed later as viral pharyngitis [40], flushing and
chest tightness [44], lip angioedema and cough [40], and
uvula/pharyngeal edema [85]. However, in other US clin-
ical trials that collectively included over 1000 patients,
there was no use of the epinephrine autoinjectors for
SLIT-related reactions [46,51,52], and epinephrine auto-
injectors are not routinely prescribed or recommended
in countries where SLIT is registered and commercially
available. The relatively rare and potentially inappropri-
ate use of injectable epinephrine in these studies raises
concerns about the benefits and harms of routine
prescribing of injectable epinephrine, which may be-
come standard practice if the product information for
an FDA- approved SLIT formulation includes this rec-
ommendation. In addition, the US clinical trials re-
quired that the first SLIT dose be administered in the
study site. Administration of the first dose in a medicallyTable 6 Characteristics of the SLIT-induced anaphylaxis repor
Author, year [reference] Sex (age) Allergen (producer) Phase
De Groot, 2009 [79] M (13) Grass (Grazax, ALK-Abellò) First dos
De Groot, 2009 [79] F (27) Grass (Grazax, ALK-Abellò) First dos
Blazowski, 2008 [80] F (16) HDM (Staloral, Stallergenes) Mainten
(60 drop
Eifan, 2007 [81] F (11) Mixture (dust mite + grass
pollen mix (Stallergenes)
Mainten
Dunsky, 2006 [82] F (31) Alternaria, cat, dog grass,
ragweed, (Greer)
2nd day
Antico, 2006 [83] F (36) Latex End of r
SC: subcutaneous IM: intramuscular.supervised setting has never been a requirement in the
European Union.
Allergen dose, formulation, and adverse reaction rate
The literature does not appear to show a consistent
correlation between the administered SLIT dose and the
rate or severity of AEs [69]. For example, one study of dust
mite–allergic asthmatic children that employed a relatively
low-dose dust mite SLIT (15 mcg cumulative monthly
dose [CMD] of Der p 1) reported a systemic reaction rate
of 0.46% per dose [88]. In contrast, another study of dust
mite–allergic asthmatic children treated with a CMD 50
times greater (783 mcg CMD of mixed mite) reported no
serious AEs and no significant difference in the incidence
of AEs between the SLIT and placebo groups [89]. A
relationship between dose and the frequency and severity
of AEs has been demonstrated in some allergen dose-
response studies [90,91], but so far a “maximum tolerated
dose” has not been documented for SLIT.
Tolerability may vary with the extract and formulation.
A dose-response study compared the safety of 6 doses of
ragweed tablets (3, 6, 12, 24, 50, or 100 U Amb a 1) inted in literature
Onset Description Epinephrine
e 15 min Generalized urticaria, swelling
of tongue
No
e 5 min Abdominal cramps, asthma,
generalized itching, hypotension
Yes (SC)
ance overdose
s)
10 min Hypotension-collapse, flushing,
urticaria
Yes (IM)
ance 3 min Abdominal pain, chest pain,
fever, nausea
Not specified
of updosing 5 min Angioedema, dizziness, dyspnea,
generalized itching
No
ush buildup 10 min Asthma, generalized urticaria Not specified
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cruitment to 50 U Amb a 1 was discontinued, and the
100 U Amb a 1 dose was not initiated after 3 subjects
experienced systemic reactions at doses ≥24 U Amb a 1
[91]. In contrast, the treatment and placebo groups had
similar frequencies of systemic AEs in an RDBPC dose-
response study of 115 ragweed-allergic rhinitis patients
randomized to receive 4.8 or 48 mcg of Amb a 1 sublin-
gual ragweed extract solution [46]. Similar safety was
demonstrated with this same ragweed extract solution in
a subsequent RDBPC study of 429 patients who received
up to 50 mcg of Amb a 1 or placebo [92]. The difference
in tolerability between similar ragweed doses may be a
result of the formulation (tablet versus extract solution).
However, studies with grass pollen sublingual tablets
and extract solution have demonstrated comparable dose
efficacy and safety [54,93,94]. One study comparing the
safety of 7 doses of grass tablets, with the highest dose
equivalent to 200 mcg of Phl p 5, reported no treatment-
related AEs that were serious, systemic, or led to with-
drawal [90]. These studies reaffirm that an effective and
safe dosing regimen will need to be established for each al-
lergen extract formulation.
Induction schedule
In contrast to SCIT, accelerated induction schedules with
SLIT do not appear to be associated with a greater risk
of systemic reaction. Rush, ultra-rush, and no-induction
SLIT schedules seem to be tolerated as well as multi-dose,
multi-week induction schedules.
Several large multicenter studies, collectively including
over 1000 patients, investigated the safety and efficacy of
grass and ragweed tablets administered without an updos-
ing phase. There were few reported systemic allergic reac-
tions, primarily WAO Grade 1 or 2, and no Grade 4
reactions [40,44,51,94,95]. Similar safety has been reported
with SLIT ultra-rush and rush induction schedules, which
allow patients to achieve the target maintenance dose
within minutes to hours [46,96-98].
Although the induction phase does not seem to influ-
ence the SLIT AE rate, many studies have reported that
more AEs occurred during the induction phase than
during the maintenance phase. Most occur within the
first few days to weeks of treatment and infrequently
after this initial phase. The local AEs appear to resolve
without any medical interventions, such as dose adjust-
ments or antihistamines. In studies that have utilized
discontinuous schedules (pre- and coseasonal), the fre-
quency and intensity of AEs appeared to decline in the
later courses of SLIT treatment [3,72,99].
SLIT in young children
Immunotherapy guidelines do not specify a particular
lower age limit for initiating AIT. SCIT is often notprescribed to young children, primarily because of con-
cerns that they may have difficulty cooperating with an
immunotherapy program and, in particular, in commu-
nicating symptoms of systemic reactions. However, stud-
ies that have evaluated the safety of SCIT in children
less than 5 years old have reported a similar incidence and
severity of AEs as in other age populations [100,101]. Cit-
ing these studies, the third update of Allergen Immuno-
therapy: A Practice Parameter [102] states that:
Immunotherapy can be initiated in young children
less than 5 years of age if indicated. Indications should
be based on the severity of the disease, risk/benefit
ratios, and the ability of the physician to correlate the
clinical presentation with appropriate and obtainable
allergy testing.
The preventive benefits of AIT may be greater if initi-
ated early in the course of the allergic disease [103].
SLIT’s favorable safety profile and a regimen that does
not require needles or frequent trips to a medical clinic
may make this disease-modifying treatment more avail-
able and attractive to young children and their care-
givers, allowing for treatment initiation at an age where
disease progression may be more easily influenced.
Observational and postmarketing survey studies spe-
cifically designed to evaluate the safety of SLIT in
young children found that most reactions were mild or
moderate and resolved without treatment [104-106].
Dose reduction by changing from a sublingual-swallow
to a sublingual-spit method controlled gastrointestinal
reactions in one study [106]. One further study with
dust mite SLIT in 138 children aged 2–5 years with
asthma or rhinitis showed only mild to moderate local
AEs [107].
Recognizing the importance of treatment adherence for
SLIT efficacy, one study evaluated the adherence to SLIT
in 150 children <6 years old over a 2-year period [74].
Overall, 45% of the children discontinued treatment. The
percentage of discontinuations was significantly higher in
the children <4 years old than in the older children, with
all discontinuations in this age group occurring within the
first 3 months of treatment. The most common cause for
withdrawal in the children <4 years old was “… the sub-
jective discomfort in keeping under the tongue drops/
tablets, or children’s refusal, without apparent side ef-
fects.” The parents attributed their children’s refusal to
unpleasant taste. There was no difference in adherence
between tablets or drops in the older children, but tab-
lets were discontinued in 100% of the children <4 years
old. There was one asthma reaction leading to SLIT
withdrawal in the <4-year-old group. The authors spec-
ulated that the local SLIT side effects are more trouble-
some in young children and suggested that SLIT would
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younger children.
Multiallergen SLIT
Two of the case reports of SLIT anaphylaxis involved
multiallergen SLIT, and most of the SLIT studies
employed single allergens. However, 2 studies specifically
designed to compare the safety of single versus multial-
lergen SLIT in adults and children found no significant
differences in terms of frequency or severity of treatment-
related AEs [108,109]. Other studies designed to compare
the efficacy of single and multiallergen SLIT have reported
similar safety for both [110,111]. Collectively, these studies
suggest that multiallergen SLIT is not associated with a
greater safety risk than single allergen treatment. However,
questions remain as to whether multiallergen immuno-
therapy is effective [68,110].
SLIT safety special considerations: autoimmunity,
immunodeficiency, and pregnancy
In general, AIT has been studied in adults and children
without any significant concomitant chronic illness, and
no controlled studies have evaluated effectiveness or
risks associated with immunotherapy in patients with
immunodeficiency or autoimmune disorders. However,
case reports [112-114] and registry studies [115] have
been reassuring in terms of the safety of AIT in these con-
ditions. The immunotherapy practice guidelines state that
“Immunotherapy can be considered in patients with im-
munodeficiency and autoimmune disorders” [102]. Most
of these studies were based on SCIT, but these findings
should apply to SLIT because the immunological mechan-
ism between the routes are thought to be the similar [8].
Generally, AIT is not initiated during pregnancy but can
be continued without updosing if treatment was begun
prior to conception. There have been no randomized,
controlled, prospective studies investigating the safety of
AIT during pregnancy. However, retrospective studies of
women who received SCIT during pregnancy suggest that
there is no greater risk of prematurity, fetal abnormality,
or other adverse pregnancy outcome [116,117]. A 6-year
study evaluating the safety of SLIT during pregnancy
found a lower incidence of abortion, perinatal mortality,
prematurity, toxemia, and congenital malformation in 155
women who received SLIT than in the general population
[118]. In 24 women, SLIT was initiated for the first time
during pregnancy.
Although these studies are reassuring in terms of the
safety of SLIT during pregnancy, the numbers are small
and the risks and benefits should be considered on an
individual basis. A similar approach should be taken when
considering SLIT for patients with an immune deficiency
or autoimmune disorder, conditions for which there have
been no studies specifically investigating the safety ofSLIT, although there is indirect evidence from SCIT sup-
porting the safety of AIT in these conditions.
SLIT safety: patient selection and instructions
Because this treatment is administered at home without
direct medical supervision, patients should be provided
with specific instructions regarding how to manage ad-
verse reactions or unplanned treatment interruptions,
when and what to report to the prescribing physician,
and situations when SLIT should be withheld (e.g.,
oropharyngeal infection, oral abrasion, acute gastro-
enteritis, asthma exacerbation). Careful consideration
should also be given to the ability of the patients or their
families to adhere to these instructions and the treat-
ment regimen.
SLIT safety summary
In general, SLIT appears to be associated with fewer and
less severe AEs than SCIT. Oropharyngeal reactions are
the most common AEs with SLIT, but other reactions,
such as asthma, urticaria, and abdominal pain have been
reported. There have been a few case reports of anaphyl-
axis with SLIT, including 2 reports of anaphylaxis with
the first dose. Risk factors for SLIT AEs have not been
clearly established. Some studies suggest a greater fre-
quency of AEs during the induction phase than in the
maintenance phase, but there does not seem to be a re-
lationship between induction schedule and SLIT AEs,
with ultra-rush and no-induction schedules reported as
being well tolerated in several studies.
Because this treatment is administered in a medically
unsupervised setting, it is particularly important for
further studies to be conducted to help identify and
characterize SLIT risk factors, appropriate patients, pa-
tient instructions to minimize and/or treat AEs, and
methods or interventions to monitor and optimize pa-
tient adherence.
Unmet needs
Several issues regarding the safety of SLIT remain
unresolved:
 Is SLIT safe in individuals with moderate to severe
asthma?
○ Are there specific precautions to be taken for
asthma patients before taking SLIT, such as
obtaining peak flow measurement?
 Is SLIT safe in patients who have had systemic
reactions with SCIT?
 Interruptions in treatment:
○ After how long an interruption between doses is
it safe to resume the usual dose
▪ during the updosing phase?
▪ during the maintenance phase?
Canonica et al. World Allergy Organization Journal 2014, 7:6 Page 17 of 52
http://www.waojournal.org/content/7/1/6○ Would the recommendations for interruptions
in maintenance treatment be different for
regimens with an updosing phase than regimens
without an updosing phase?
 Is it safe to administer all formulations of SLIT
without induction? Or do some require an
updosing phase?
 Are oropharyngeal infections or lesions (e.g.,
apthous ulcers, gingivitis, eosinophilic esophagitis)
risk factors for SLIT systemic reactions?
 Under which clinical situations should a SLIT dose
be withheld (e.g., recent respiratory tract infection,
recent exacerbation of asthma, gastroenteritis)?
 Is SLIT safe in pregnant or breastfeeding women?
 Is SLIT safe in patients with immune deficiency and
autoimmune conditions?
 Are there any risk factors that identify which
patients may experience a systemic reaction with
SLIT?
Chapter 6: Impact of sublingual immunotherapy
on the natural history of respiratory allergy
 Allergen-specific immunotherapy may alter the
natural history of respiratory allergy by preventing
the onset of new skin sensitizations and/or reducing
the risk of asthma onset.
 Several randomized, double–blind, placebo-
controlled (RDBPC) studies in grass pollen rhino-
conjunctivitis confirm the persistence of the clinical
effects of SLIT for at least 1–2 years after treatment
discontinuation.
 There are 2 randomized, open, controlled studies
suggesting that SLIT reduces the risk of asthma
onset in children with rhinitis. A 5-year prospective
RDBPC trial [119] (n = 812 at randomization) in
children aged 5–12 years with grass pollen seasonal
rhinoconjunctivitis will complete in 2015 and should
provide more definitive information.
 Two open, randomized studies have shown that
SLIT reduces the onset of new allergen
sensitizations. Further RDBPC trials are required.
Sublingual immunotherapy (SLIT) has been shown to
be effective in reducing symptoms and medication re-
quirements and in improving quality of life in adults and
children with seasonal allergic rhinitis. A particular fea-
ture of immunotherapy, unlike usual anti-allergy drugs,
is the ability to modify the course of allergic disease.
Long-term benefits continue after discontinuation of
treatment, and evidence supports reductions in the on-
set of new sensitizations and the likelihood of progres-
sion from rhinitis to asthma in patients with seasonal
allergic rhinitis treated for 3 years with subcutaneousimmunotherapy (SCIT) (reviewed in the 2009 WAO
SLIT Position Paper [9]).
In the previous WAO SLIT position paper [9], prelim-
inary data were presented supporting the long-term ben-
efits of SLIT, largely from small and/or non-randomized
controlled trials. There are now convincing data from
RDBPC studies of grass pollen SLIT [4,96,120] that show
persistent clinical benefit for at least 1 or 2 years follow-
ing treatment discontinuation (Table 7), illustrating that
SLIT as well as SCIT is able to modify the disease and
provide long-term benefit. There is also a single open,
pharmacotherapy-controlled study in mite-allergic adults
followed for a total of 10 to 12 years [121] that provides
preliminary data that house dust mite SLIT may provide
long-term protection after treatment discontinuation, al-
though further studies are required.
Following on from the preventive allergy treatment
(PAT) study [122], which suggested that SCIT may pre-
vent the onset of asthma for 10 years, the Grass Asthma
Prevention (GAP) trial [119] has been initiated and is
due to be completed in 2015. In this study, 810 children
aged 5–12 years who have grass pollen rhinoconjunctivi-
tis will receive sublingual single-grass pollen extract al-
lergy immunotherapy tablets daily for 3 years, followed
by 2 years of continued blinded follow up. The primary
end point is the time to the onset of asthma.
In summary, since the previous position paper there is
now good evidence for long-term efficacy after treatment
discontinuation and a disease-modifying effect of SLIT in
grass pollen rhinoconjunctivitis. Further studies to assess
the impact of SLIT for rhinoconjunctivitis on the onset of
new sensitizations and asthma are in progress. Similar
studies for perennial allergies represent an important un-
met need.
Chapter 7: Efficacy of SLIT in children
 Grass-pollen sublingual immunotherapy (SLIT) is
effective in seasonal allergic rhinitis in children
≥5 years of age.
 Grass-pollen SLIT is probably effective in seasonal
allergic rhinitis in children ≥4 to <5 years of age.
 Grass or house dust mite (HDM) SLIT can be used
for allergic rhinitis in children with asthma.
 Pre-coseasonal SLIT with grass pollen in children
might be as effective as continuous treatment.
 SLIT must not be suggested as monotherapy for
treating asthma.
 House dust mite SLIT is effective in children with
asthma and allergic rhinitis.
 More large randomized trials are needed, especially
with HDM SLIT in children.
 No new data on the preventive effect of SLIT in
children have been published.
Table 7 Long-term efficacy of sublingual immunotherapy after discontinuation of treatment
First author
publication
year [ref]
Diagnosis Age
(years)
Study design n Baseline Allergens Allergen
daily dose
Treatment
duration
(years)
Years after
cessation
Years
blinded
n End of
follow-up
Main results
OTT
2009 [5]
ARC 8–65 RDBPC 213* 5 grass pollens:
D. glomerata,
P. pratensis, L.
perenne, A.
odoratum. and
P. pratense
300 IR/mL
(21 mcg of
Phl p 5)
3 1 3 91** In the third season, the median of the
combined symptom and medication scores
had decreased by -–44.7% in the SLIT group
and −14.7% in the placebo group compared
with baseline values. Symptom scores were
reduced by 39.7% in the SLIT group and 1.51%
in the placebo group (P < 0.05).
Reductions in combined scores (P = 0.0508) and
symptom scores (P = 0.0144) were observed in
the participants treated with SLIT during
follow up.
Marogna
2010 [6]2
AR with or
without
asthma
18-–65 Open,
pharmacotherapy
controlled trial
78 House dust mite 10,000 RAST
units/mL;
3 times per
week
3 to 5 10 to 12 None 59 The clinical effects persisted for 7 years for those
on SLIT for 3 years and for 8 years for on those on
SLIT for 4 or 5 years. New sensitizations occurred
in all the control subjects and in up to 25% of
those on SLIT.
Durham
2012 [4]
ARC with
or without
asthma
18–65 RDBPC 634* Single grass tablet:
Phleum pratense
75,000 SQ-
T/2,800 BAU
(15 mcg of
Phl p 5)
3 2 5 241 The mean rhinoconjunctivitis daily symptom
score was reduced by 25% to 36% (P ≤ 0.004)
in the SLIT group compared with the placebo
group over the 5 grass pollen seasons. The
rhinoconjunctivitis DMS was reduced by 20% to
45% (P ≤ 0.022 for seasons 1–4; P = 0.114 for
season 5), and the rhinoconjunctivitis combined
score was reduced by 27% to 41% (P ≤ 0.003)
in favor of active treatment.
The percentage of days with severe symptoms
during the peak grass pollen exposure was in all
seasons lower in the active group than in the
placebo group, with relative differences of 49% to
63% (P ≤ 0.0001). Efficacy was supported by
long-lasting significant effects on the allergen-
specific antibody response.
Didier
2013 [3]
ARC 18–51 RDBPC 633* 5 grasses tablet:
D. glomerata, P.
pratensis, L.
perenne, A.
odoratum, and
P. pratense
300 IR (25
mcg - group
5 major
allergens)†
3 1 3 435 For the year 4 pollen period, significant
reductions in the AAdSS LS means were
observed for both the 300IR (4M) and 300IR
(2M) groups, −22.9% and −28.5% respectively
(compared to placebo).
There was no significant difference between
the 2 active treatment groups, and no impact
of asthma or sensitization status on the
efficacy results.
ARC: Allergic rhinoconjunctivitis; AR: Allergic rhinitis; RDBPC: Randomized, double-blind, placebo-controlled trial; SP: Supralingual; LS: Least-Squares; AAdSS: Average Adjusted Symptom Score; DMS: Daily medication
score; IR: Index of Reactivity; SQ-T: Standardized Quality Tablets; BAU: Bioequivalent allergy unit;
*Randomized (n); **Per protocol population; †Placebo or a 300IR tablet daily beginning either 4 months (4M) or 2 months (2M) prior to each pollen season and continuing for its duration for 3 consecutive years.
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original studies that had been published since the first
WAO SLIT position paper [123], beginning in 2009
(PubMed search with the terms SUBLINGUAL AND IM-
MUNOTHERAPY and the filters: publication date 2009–;
Humans; Clinical Trial; Randomized Controlled Trial;
Child: birth–18 years). Twenty-six articles were excluded:
2 had already been included in the original WAO SLIT
paper [124,125], 1 was on subcutaneous immunotherapy
(SCIT), 1 was for a non-allergic indication, and 22 had al-
most exclusively adult patients. The remaining 25 original
articles form the basis for this update.
All included papers were evaluated with the GRADE
system on the quality of scientific evidence from 4
(high) to 1 (very low), as described [126]. A table with
the complete GRADE evaluation can be found in a re-
cent publication [127].
Three of the 25 papers only evaluated the safety of
SLIT. Of the 21 that evaluated efficacy, the prime aller-
gic disease was allergic rhinitis/rhinoconjunctivitis in 14
papers, allergic asthma in 3, both asthma and rhinitis in
3, and food allergy in 2 (Table 8).
Pediatric SLIT and allergic rhinitis
The efficacy of grass pollen SLIT tablets for seasonal al-
lergic rhinitis in children had already been established in
the first WAO SLIT position paper, based primarily on
the results of 3 large trials done in Europe [124,125,128].
Two of these trials [125,128] had an extension published
within the time frame reviewed here: one of them in-
cluded an analysis of subgroups [129], and the other
showed mechanistic data [25]. Halken et al. [129] showed
that the 5-grass tablet was just as effective in school chil-
dren (5–11 y) as in adolescents (12–17 y), and there was
enhanced efficacy during the peak pollen season. The tab-
lets were also highly effective if eye symptoms were evalu-
ated separately.
A review of SLIT trials performed in the United States
(US) was recently published [130]. It highlighted one
new high-quality trial conducted among American chil-
dren with grass-pollen allergic rhinoconjunctivitis [40]
as well as another randomized, double-blind, placebo-
controlled (RDBPC) trial conducted with a highly con-
centrated grass pollen sublingual solution [54].
There are several other SLIT studies with grass pollen
that do not add much to the already accepted profile
mentioned above, and most of them are of lower quality.
However, some of them explored new aspects of SLIT.
A- HDM SLIT study that recruited patients from pri-
mary care practices reported no effect of 2 years of treat-
ment [53]. However, the clinical trial had several flaws
(see Chapter 4) and is rated GRADE 2. A seemingly
positive HDM SLIT trial was conducted in Japan, but
the scientific quality of this study was GRADE 1 [66].Pediatric SLIT and asthma
There were 2 randomized trials directly studying SLIT
in allergic asthma. Eifan et al. demonstrated that 1 year
of treatment with HDM SLIT was more effective than
pharmacotherapy in controlling asthma symptoms, medica-
tion, and visual analog scale (VAS) scores [27]. Bronchial-
and nasal-specific hyper-reactivity were also reduced. No
difference was shown between the SLIT group and a third
group treated with SCIT; however, because the study was
underpowered, no statement can be made about the
SLIT–SCIT comparison. Grass pollen extract SLIT
strongly improved asthma symptoms and medication
scores in comparison to a blinded placebo, but the study
quality was low due to a 40% dropout rate in the pla-
cebo group [131]. SLIT trials in asthmatic patients gen-
erally allow for the administration of maintenance and/
or as-needed medication; thus, SLIT must not be sug-
gested as monotherapy for treating asthma.Allergic respiratory disease: asthma and rhinitis
Four studies investigated SLIT in allergic respiratory con-
ditions in children with both allergic rhinitis and asthma
[47,62,132,133]. Three used HDM and one used grass ex-
tracts. The SCIT versus SLIT results of the HDM trial by
Yukselen et al. [62] are discussed in more detail in the
next section. Here, the SLIT versus placebo comparison
was not significant on most parameters, but there were
only 10 children in each group. Details of the other trials
can be found in the table.SCIT versus SLIT for respiratory allergy
Yukselen et al. [62] conducted an RDBPC comparison
between HDM SCIT and SLIT with a double-blind
double-dummy design and concluded that both active
treatments are effective, SCIT more so than SLIT. Al-
though the study was - underpowered, with 10 patients
in each of the 4 groups, the tendency was clear: both
treatments improved rhinitis and asthma symptoms and
medication scores, but the changes only reached statis-
tical significance in comparison to placebo in the SCIT
group. Also, the response to nasal challenge with HDM
improved in both groups, but the bronchial HDM chal-
lenge dose improved only in the SCIT group, accompan-
ied by a reduction in the post-challenge eosinophil count
in broncho-alveolar lavage. Similar immunologic changes
(HDM-IgE reduction, IL-10 rise) were seen after both
SCIT and SLIT, with the exception of HDM-IgG4, which
only rose in the SCIT group, reaching a statistically signifi-
cant difference with the SLIT group [62].
A similar study was conducted by Eifan et al. [27]. In a
randomized trial, they studied SLIT versus SCIT versus
pharmacotherapy alone. Although the study groups were
somewhat larger, the study was still underpowered, and
Table 8 Clinical efficacy of SLIT in children: update 2009 to September 2012
AUTHOR, year
[reference]
Age (y) A/P Drop-out
(A/P)
Allergen,
drop or
tablet
Duration Dose (mcg/
dose and
dosing
frequency)
Versus
SCIT
Disease Manu-
facturer
Main positive results Negative results
Randomized, double-blind, placebo-controlled
Wahn 2012 [11] 4–12 158/49 26/2 6-grass drops 8 mo 40 mcg group
5 daily
NS RC(A) All
Pharm
SLIT vs placebo: Change
in pre-post treatment
higher for symptom-
medication, symptom, &
medication scores in SLIT
group. Higher rate of
positive response with
SLIT (≥40% decrease of
the AUC of the symptom-
medication score).
SLIT vs placebo:
Mean number of well
days
Stelmach, 2012
[17]
6–18 Cont 20 1 Grass, drops 2 y 10 mcg group
5 daily Cont:
for 2 y
NS RCA Stal Both active groups vs
placebo: Significant
improvement, med+symp
score, symptom score,
FeNO.
Medication score in
continuous group.
Pre-co 20 3
Plac 20 2 Pulmonary function
tests, Metacholine
challenge
Pre-co: 2 × 6
mo
Pre-coseasonal group vs
placebo: significant
reduction of med score
De Bot, 2012 [12] 6–18 126/125 15/17 Mite, drops 2 y 2.03 mcg Der
p 1 twice per
week. Total
cumulative
dose (2 y): 435
mcg
NS RC ART No positive results Total nasal symptom
score, QoL, med
score, well days
Yukselen 2012 [19] Mean 10
(± 3)
SLIT 11 1 Mite, drops 1 y (+1
y obser-
vation)
Dpt+Df: SLIT:
1000 TU/mL:
28 drops 3×/
week.
4.2 R&A AllerPhar SCIT vs SLIT: SCIT
reduced asthma
symptoms significantly
more than SLIT.
SLIT vs placebo: NS
for all clinical
parameters. NS for
rhinitis and asthma
VAS.
SCIT 10 0
Plac 11 1
SCIT vs placebo: Rhinitis
symptoms, asthma
symptoms, total
symptoms, rhinitis meds,
and asthma meds
improved. VAS score was
significantly reduced for
both rhinitis and asthma.
SLIT and SCIT vs.
baseline year: both
improved almost all
clinical parameters
SCIT: 3368 TU/
4 wk
SCIT vs SCIT: NS for
rhinitis symptoms and
meds and asthma
meds.
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Table 8 Clinical efficacy of SLIT in children: update 2009 to September 2012 (Continued)
Blaiss 2011 [10] 5–17 175/169 33/29 Grass,
tablets
6 mo 15 mcg Phl p5
daily
NS RC(A) ALK SLIT: Improvements in
daily symptoms (25%),
daily meds (81%), total
score (26%), and QoL
(18%) (all P ≤ 0.04 vs.
placebo).
Asthma symptoms
Kim 2011 [20] 1–11 11/7 0/0 Peanut,
drops
12 m 2000 mcg
daily (8
pumps)
No data on
SCIT dosing
Peanut
allergy
Greer Food challenge:
Significantly greater safe
ingestion of peanut than
placebo group;
improvements in skin
prick test and basophil
responsiveness.
No statistically
significant changes
were found in IL-13
levels, the percentage
of regulatory T cells,
or IL-10 and IFN-
gamma production.
Yonekura, 2010
[26]
7–15 20/11 1/2 Mite, drops 1 y 0.5 mcg Der f
1 once a week
20 RC TOR Active-placebo: week 30:
reduced symptom score.
Active-placebo:
combined sympt-med
score
Change from initial
(wks 0-3) to end (wks
37-40) in the active
group: Decrease in
symptoms and symptom-
med score.
Mösges, 2010 [27] 6–14 27/27 0/0 Tree pollen
drops
Updosing 30-90-150-300
IR each 30 min
NS Asthma Stal Not an efficacy trial No difference in PFR
change between the
active and placebo
groups during
updosing and no
serious AEs.
Halken 2010 [7]
(additional data to
Wahn 2009 [3])
5–17 TOTAL 278 :
131/135
Grass
tablet
6 mo 25 mcg Phl p
5 daily (300IR)
RC Stal Active-placebo: Total
symptom score reduced
over whole season and at
peak pollen season. Nasal
and ocular symptoms
reduced. Rescue
medication used less
during whole and peak
pollen season.
None
Nieminen 2010 [8]
(subgroup of study
Valovirta 2006 [6])
5–15 10 low10 high
10 Plac
Birch-alder-
hazel mix,
drops
2 y 24,000 SQ-U/
wk (3.6 mcg
group 1),
200,000 SQ-U/
wk (30 mcg
grp 1)
0.5 and 4.5 RC(A) ALK Mechanistic study: Patients with elevated
symptom and medication score: increase in
allergen-induced PBMC mRNA IL-17 expression;
a positive and dose-dependent correlation SMS
and IL-17 production. High-dose group vs pla-
cebo at 2 y: increase in FOXP3 mRNA expression.
FOXP3 mRNA changes correlate with IL-10 and
TGF-beta mRNA.
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Table 8 Clinical efficacy of SLIT in children: update 2009 to September 2012 (Continued)
Stelmach 2009 [15] 6–17 20/15 5/10 Grass,
drops
pre-co for
2 y
10 mcg group
5 grass drops
daily
NS A Stal SLIT vs Plac: asthma
symptoms, nasal symptoms,
nasal+asthma symptoms,
medication score, nasal
+asthma+med score.
SLIT vs Plac: ocular
symptoms, total
Asthma+nose+eye
symptoms
Randomized controlled
Keet 2012 [21] 6–17 SLIT 10 0 Milk
protein
drops
14 mo SLIT 7 mg,
OIT-A 2000
mg, OIT-B
1000 mg milk
protein daily
NS CM Food challenge passed
by more OIT pts vs SLIT
alone (SLIT 1, SLIT/OITB 6,
SLIT/OITA 8)
3 of 6 desensitized
OITB pts, 3 of 8 OITA
pts regained
hyperreactivity after 6
wk milk avoidance
SLIT start then:
OIT-A 10 OIT-B
10 0
0
Pajno 2011 [23] 8–16 Cont/coseasonal:
40/40
3/5 Grass
drops
Cont: 3 y 8 mcg group
5, 5 times/
week
NS RA Stal Continuous vs coseasonal:
1st year: symptoms+med,
symptoms, chest
symptoms, and med
scores improved more
with continuous SLIT.
3rd year: no difference
in clinical outcomes
between continuous
vs coseasonal SLIT
Coseasonal:
3 × 4 mo
Keles 2011 [24] 5–12 SCIT 15 4 HDM 18 mo SCIT: 13 mcg
Der p+f 1/mo
0.75 A (and
R)
ALK Active vs
pharmacotherapy:
SCIT→SLIT: all clinical
parameters improved at
12 mo, half at 4 mo. SCIT:
all but rhinitis score
improved at 12 mo. SLIT:
only asthma med
improved at 12 mo.
SLIT vs
pharmacotherapy:
only asthma med
improved.
SCIT: alum
adsorbed,
SLIT dropsSLIT 15 2
SLIT: 0.75 mcg
Der p+f 1 3
times/weekbuild-up SCIT 1 Pharmacotherapy: no
clinical parameters
improvedthen SLIT 15
Pharmacotherapy
15 3 Within group: Asthma
medication and asthma
attacks reduced at 4, 12, 18
mo compared to baseline
with SCIT and SCIT→SLIT,
reduced at 12 mo with SLIT.
Marogna 2011 [121] 5–17 SLIT 34/
Cetirizine 34
3/4 HDM (not
specified drop-tab)
36 mo 1000 AU 1/w ? R2+A Lofarma SLIT non-smoking:
clinical scores, nasal CS, B2
use, and pulmonary
function tests all improved
Cetirizine + non-
smoking: clinical and
pulmonary function
tests50% of each
group: passive
cigarette smoke* SLIT smoking: all showed
a trend to improvement,
but only MEF25 was
statistically significant.
Cetirizine + Smoking: all
parameters worsened
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Table 8 Clinical efficacy of SLIT in children: update 2009 to September 2012 (Continued)
Pozzan 2010 [28],
low quality, only
once per year
evaluation by
patient
10–65 SLIT 34, Control
18
1/0 Alternaria
drops
36 mo 1 dosis
SLITone daily
? R (A) ALK Active vs control:
Symptom score reduced,
med score reduced
Active vs control: No
med score reduction
Active pre-post: med
score reduced
Eifan 2010 [14] 5–10 y SLIT16, SCIT16,
Pharma 16
1/2 HDM SCIT:
alum
adsorbed,
SLIT drops
12 mo Dosing not
clear (SLIT: 3.8
mcg Der p+f 1
3 times/wk
2.2? A (R) ALK SLIT and SCIT vs
pharmacotherapy: total
rhinitis symptoms, asthma
symptoms, medication,
and VAS score.
SLIT vs SCIT: no
difference in total
rhinitis symptoms,
asthma symptoms,
medication, or VAS
score.SCIT: 22.2 mcg
Der p+f 1/m)
Open controlled, no randomization
Aquistapace 2009
[29]
6–18 cases 90/
control81
NA Several,
drops
2 y varied NS RC(A) ALK
(SLITone)
SLIT vs controls: reduced
symptoms, med score,
new sensitizations.
SLIT vs control:
asthma symptoms
Observational, prospective
Lee 2011 [13] mean
14.7
(4–53)
Mono-sensitized
70 Multi 64
NS HDM,
drops
12 mo 5 drops 1000
STU/mL Dpt-
Df 3/week
NS R ALK none Mono- and
multisensitized
symptom and
medication scores: all
improved. No
difference between
any variable.
Roger 2011 [22] 4–15
(total
subjects
4–64)
122 (total
n = 218)
none HDM,
drops
Updosing Every 30 min:
30-60-120-
240IR
30 R and/
or A
Stal 8 systemic reactions (3
moderate), all continued
SLIT. Higher frequency of
AEs in asthmatic patients.
No difference in
frequency or severity
of AEs in patients
under 15 y.
Observational, retrospective
Trebuchon, 2012
[18]
735 pts
5–18
(1289
pts total)
No active or
control groups
No active
or control
groups
HDM,
drops
2+ y Variable, most
300IR daily
No
comparison
possible
Resp.
allergy
Stal,
some
ALK
Descriptive study of how SLIT is given, dosing
schedules, duration, etc. Treatment ‘(very)
effective’, according to physician: 82%. Reduction
in asthma medication: 26% stopped taking ICS.
*parental smoking (at least 20 cigarettes per day).
Abbreviations: AE, adverse event, A/P, active/placebo; NS, not signficant; HDM, house dust mite; Cont, continuous; plac, placebo; pre-co, pre-coseasonal; QoL, quality of life; TU, therapeutic units; AU, area under the
curve; med(s), medication(s); OIT, oral immunotherapy; AE, adverse event; VAS, visual analog scale; pts, patients; PFR, peak flow rate; SAE, serious adverse event; RC, rhinoconjunctivitis; RCA, rhinoconjunctivitis and
(mild) asthma; [I]CS, [inhaled] corticosteroid; STAL, Stallergenes; GRE, Greer; ALK, ALK-Abelló; TOR, Torii Pharmaceutical, Japan.
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of the many parameters examined.
Food allergy
Early work in food SLIT suggests some benefit in terms of
desensitization, but this has been limited to a few small
trials. A small US study investigated SLIT for peanut-
allergic children in an RDBPC trial [134]. Data suggested
that SLIT could induce desensitization, but long-term
studies are needed to see if tolerance will develop. Keet
et al. [135] compared the efficacy of oral immunotherapy
(OIT) versus SLIT for cow’s milk allergy in children. This
study showed that OIT was superior to SLIT alone at in-
ducing desensitization to cow’s milk, but desensitization
was lost as early as 1 week off therapy.
New insights
Research published since 2009 has provided some inter-
esting new insights into the effects of SLIT.
 Age: 2 of the rhinitis studies [54,66], 1 also including
asthmatic children [66], and 1 safety trial [97]
included children ≥4 years old, and 1 food-allergy
trial included children ≥1 year old [134]. Therefore,
we now have medium-quality preliminary evidence
of SLIT efficacy for rhinitis in children from 4 years
of age [54].
 Two medium quality trials investigated continuous
versus co- or pre-coseasonal grass SLIT
administration:
○ A pre-coseasonal course of grass SLIT in drops
over 2 consecutive seasons was compared with
continuous administration of SLIT for 2 seasons
and placebo in children with allergic rhinitis
[47]. Although the study was underpowered to
show intergroup differences, both active treat-
ments reduced the combined symptoms and
medication score statistically significantly better
than placebo. Only the pre-coseasonal schedule
reduced the medication score as well.
○ Pajno et al. demonstrated that 3 years of
continuous or co-seasonal SLIT with grass pollen
extract had different efficacy in children with sea-
sonal asthma and rhinitis. At the end of 3 years,
both treatments were equally efficacious in redu-
cing total symptoms and lung symptoms and in
inducing immunological changes, but during the
first 2 years these changes were more pronounced
for the continuously treated group [63].
 SCIT updosing for 4 months followed by SLIT
maintenance turned out to be at least as effective as
SCIT with regard to efficacy and immunological
changes, but without the safety problems often seen
with SCIT (see efficacy chapter for further in-depthdiscussion). In this study, 2 of 13 SCIT patients
dropped out because of systemic adverse
reactions) [24].
 A French group of investigators introduced a new
efficacy variable, the adjusted symptom score
(AdSS): by adjusting the rhinitis total symptom
score for rescue medication use, the AdSS can
estimate symptom severity and the treatment effect
more accurately. Applying this variable post-hoc to
published adult and pediatric trials, the investigators
showed a reduction of the observed placebo
effect [136].
 The deleterious effect of passive smoking in children
with intermittent asthma and perennial HDM
allergic rhinitis could be partially ameliorated by
SLIT, although the improvement in β-2 use, pul-
monary function tests, and nonspecific bronchial
hyper-reactivity was more pronounced in the SLIT
group without passive smoke exposure, as was the
reduction in nasal eosinophils [132]. However, this
needs to replicated as it was an open study, and it
surely does not mean SLIT protects against passive
smoke health effects.
 A very-low-quality study [66] indicated that mono-
or polysensitized patients respond equally well to
single-allergen SLIT.
 Adherence in pre-school children was promising in
an Italian study [74].
Unmet needs
A number of issues regarding the use of SLIT in chil-
dren remain to be resolved:
 Dosing:
○ What is the optimal dose of allergens other than
grass pollen in children?
○ What is the bioavailability of drops and tablets
in children, and how will this affect the
optimal dose?
○ Is efficacy retained in SLIT with multiple
non-cross-reacting allergens?
○ What is the optimal duration of treatment
needed to maintain long-term effects?
 Indications:
○ How efficacious is SLIT in children who are
unresponsive to pharmacotherapy?
○ What is the long-term efficacy of SLIT?
○ Can SLIT prevent respiratory allergy in children
with only eczema, or persistent asthma in
children with rhinitis?
○ Can SLIT be used in children <4 years old?
 Other allergens
○ What are the safety, efficacy, and optimal dosing
of SLIT for latex allergy?
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for example to milk, peanut, or hazelnut?Chapter 8: Definition of SLIT patient selection
 To be eligible for sublingual immunotherapy (SLIT),
patients should have
○ History of symptoms related to allergen
exposure documented positive allergen-specific
IgE test.
 The allergen used for immunotherapy must be
clinically relevant to the clinical history.
 A molecular allergy diagnosis provides further
guidance for an appropriate SLIT prescription.
 Age does not appear to be a limitation.
 Single-allergen SLIT has been demonstrated to be
effective in both monosensitized and polysensitized
patients.
 Use of SLIT for latex allergy, atopic dermatitis, food
allergy, and Hymenoptera venom is under
investigation; more evidence is needed to support its
clinical use for these indications.
 SLIT may be considered as initial treatment. Failure
of pharmacological treatment is not an essential
prerequisite for the use of SLIT.
 SLIT may be proposed as an early treatment in the
therapeutic strategy for respiratory allergy.
 SLIT may be particularly indicated in the following
patients:
○ Patients whose allergy is uncontrolled with
optimal pharmacotherapy (that is, those with
severe chronic upper airway disease).
○ Patients in whom pharmacotherapy induces
undesirable side effects.
○ Patients who refuse injections.
○ Patients who do not want to be on constant or
long-term pharmacotherapy.
Molecular allergy diagnosis
The identification of disease-eliciting allergens is a pre-
requisite for accurate prescription of allergen-specific
immunotherapy. Molecular allergy diagnosis (compo-
nent-resolved diagnosis) represents a major advance for
the selection of patients eligible for AIT.
Grass pollen is a major cause of respiratory allergy
worldwide and contains a number of allergenic mole-
cules, some of which (Phl p 1, Phl p 2, Phl p 5, and Phl
p 6 from Phleum pratense, and their homologues in
other grasses) are known to be major allergens [137].
In children treated with SLIT using a 5-grass pollen
extract, sIgE and sIgG4 responses significantly in-
creased to Phl p 1, Phl p 2, Phl p 5, and Phl p 6, but
not to Phl p 7 or Phl p 12 [138]. This study confirmsthat the initial phase of SLIT with a grass pollen
extract enhances sIgE synthesis and response to the
same allergen components that induce IgE reactivity
at natural exposure.
Recently Tripodi et al. [139] reported that IgE sen-
sitization profiles to P. pratense are highly heteroge-
neous. When molecularly designed SLIT preparations
are tailored to patients’ needs, this high heterogeneity
should be taken into consideration and formulations
should be driven by the allergens identified in locally
performed population studies.
SLIT in polysensitized patients
More data are needed to validate the efficacy of sublin-
gual and subcutaneous multiallergen immunotherapy in
clinical practice in polysensitized patients. Component-
resolved diagnosis could improve the reliability of choos-
ing particular molecular components of allergens for
immunotherapy. This method provides specific informa-
tion on the molecular component of allergens, confirm-
ing or excluding true sensitizations [140].
In large-scale clinical trials of grass pollen sublingual
tablets, polysensitized patients benefited at least as much
from allergen immunotherapy as did monosensitized
patients [68]. However, in the “molecular allergy era,”
monosensitization seems to be extremely difficult to
identify, because the patient is in general sensitized to
more than one component of each allergen [141].
The IgE response to an antigenically complex whole
allergen extract includes antibodies to irrelevant mole-
cules and to highly cross-reactive allergens. IgE epitopes
may be limited to some allergenic molecules by abun-
dance and perhaps solubility, and may also be affected
by the potentially large variability between preparations
of crude extracts.
The discrepancy between the information acquired using
traditional diagnostic procedures and molecular diagnosis
emphasizes the usefulness of component-resolved diagno-
sis, at least in areas of complex sensitization to pollens, in
better determining the correct indication for allergy im-
munotherapy [142].
Chapter 9: The future of immunotherapy in the
community care setting
 The significance of primary care
○ The prevalence of allergic diseases is increasing
rapidly worldwide; the point of first contact for
most allergy patients is primary care.
○ Globally, allergic diseases are under-recognized
and under- or misdiagnosed because the
symptoms of IgE-mediated allergic disease (e.g.,
rhinitis, asthma, eczema, conjunctivitis) overlap
with many other conditions.
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frequently treated inappropriately.
 Allergy education
○ Allergy teaching should become a core part of
undergraduate and postgraduate curricula.
○ Primary care teams, in particular, require further
training in the detection, diagnosis, management
(including prevention), and treatment of allergic
disorders.
○ Pragmatic programs need to be developed for a
better patient-physician partnership.
 Delivery of SLIT in the community setting
○ Primary care physicians (PCP) and general
practitioners (GPs) should know how to select
the appropriate treatment for a patient’s illness
and should be trained to make a comprehensive
assessment and to recognize treatment failure
(inadequate therapy, improperly administered
therapy, inadequate control) and exacerbations
of illness.
○ PCPs/GPs interested in treating allergic diseases
with allergen immunotherapy (AIT) should be
trained in all aspects of SLIT, including
assessment of patients and administration of
SLIT. Emphasis should be placed on detection
and management of side effects, including local
and systemic reactions.
○ Before SLIT therapy is devolved from allergists
to primary care, carefully performed research to
identify the risks, benefits, and cost-effectiveness
of treatment will be required. This will be a re-
quirement for commissioners, and without it,
implementation is unlikely.
 Collaboration between primary care team and
allergists
○ In order to control allergic diseases, it is
essential to encourage and promote cooperation
and collaboration between primary health care
clinicians (including physicians, nurses, and
others) and relevant specialists. Currently the
status quo does not reflect this prerequisite for
successful vertical integration of allergy care.
○ Primary health care clinicians should be able to
administer SLIT under the mentorship of a
trained allergist and maintain regular liaisons
with the allergist.
○ In collaboration, the allergist and the PCP/GP
will plan the SLIT, administer it to the patient,
and arrange follow up as and when needed; they
will also jointly decide when to discontinue
therapy.
○ However, the decision whether or not to initiate
SLIT (as for SCIT) should be made by the
allergist.Introduction
Over the last 50 years or so, allergic diseases have in-
creased to epidemic proportions globally, as clearly dem-
onstrated in longitudinal population studies [143] with a
concomitant rise in hospital admissions for severe dis-
ease [144]. Allergic diseases manifest in many different
organ systems, often causing distressing and disabling
symptoms for the sufferers and their families alike. These
are currently managed suboptimally in the community
setting [145,146], and because of their relative scarcity, al-
lergy specialists are often difficult to access.
It is important that primary care physicians and gen-
eral practitioners (PCP/GPs) working in the community
have a clear understanding of allergy in order to differ-
entiate allergic from non-allergic causes, such as sensi-
tivity or intolerance, for which allergy medicines have
limited effectiveness and for which there is no role for
immunotherapy. However, H1-antihistamines (ideally sec-
ond generation) and other agents may benefit the patient
in conditions mimicking allergy (e.g., where pharmaco-
logical, hormonal, neurogenic, or other stimuli initiate dir-
ect degranulation of the mast cell, as for example with
urticaria). Many symptoms of allergy can be managed with
the judicious use of pharmacotherapy, but for some, par-
ticularly where medications are not effective or where
very-long-term treatment is required, AIT offers the pro-
spect of a cure. Subcutaneous immunotherapy (SCIT) was
once available in the community but, in some countries,
was withdrawn due to safety concerns (see Immunother-
apy below). The advent of sublingual immunotherapy
(SLIT) now offers the possibility of once again providing
immunotherapy in the community setting.
The language of allergy
Most patients with allergic diseases consult primary care
physicians [147], but many people consult their primary
health care teams with wide-ranging symptoms that may
or may not be caused by allergy; the most common of
these are rhinitis, asthma, and eczema. Allergy is a set of
signs and symptoms triggered by release of chemical
mediators from the degranulation of mast cells in re-
sponse to crosslinking of IgE molecules bound to the
membranes of these mast cells by an allergen. However,
the term “allergy” is loosely used by both patients and
health care clinicians, with patients ascribing many symp-
toms to an allergic cause when a carefully taken history re-
veals this is not the case [148,149].
Similarly lax use of the term by clinicians creates fur-
ther misunderstanding and misdiagnosis, for example,
describing the watering of eyes while cutting onions as
an allergic reaction, or suggesting that the flushing of
the face on exposure to strong sunlight is a “solar al-
lergy”. We have a duty of care to our patients to attempt
to make the correct diagnosis by taking a careful history
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tions [150]. Failure to meet patients’ needs leads them to
seek help from alternative practitioners who may do
more harm than good, and often at great expense to the
patient.
Educational needs
In many medical schools, the subject of allergy is not
given a high priority or even included in the medical
curriculum. This is compounded by the paucity of al-
lergy education given to or acquired by those working in
the community setting [151-153]. A description of those
educational needs is beyond the scope of this statement
but has been addressed elsewhere [154,155]. It is impera-
tive that clear educational messages are made available to
health care planners and the general public concerning
what is, and is not, allergic disease and what treatments
are and are not effective [156]. The educational needs of
today will need to be revisited frequently in order to main-
tain relevance in a dynamic therapeutic field with an
evolving system of language and definitions [157].
Allergy management
Allergy management consists of a variety of strategies,
foremost of which is avoidance of the offending allergen.
This, of course, may not be possible, such as with the
ubiquitous house dust mite (HDM) [158], but for other
allergens, for example, peanuts or shellfish, avoidance is
currently the only reasonable course of action. Many
allergies can be managed by the judicious use of medica-
tions. For some diseases, such as rhinitis and asthma,
there are clear guidelines for medication use, such as
those from Allergic Rhinitis and its Impact on Asthma
(ARIA) [159], Global Initiative on Asthma (GINA) [160],
and the International Primary Care Respiratory Group
(IPCRG) [161]. The need and priorities for research into
best practices for diagnosis and management of allergy
and asthma in primary care have been detailed by the
IPCRG in a global Delphi exercise [162,163] and by the
European Academy of Allergy & Clinical Immunology
(EAACI) [164]. The importance of the PCP/GP for diag-
nosis and management of allergy in low- and middle-
income countries has also been highlighted [165].
Rescue medications may be needed to treat some aller-
gic conditions, for example, use of adrenaline in acute
anaphylaxis or oral corticosteroids for an exacerbation
of asthma or severe acute intermittent rhinitis. Similarly,
routine medications such as antihistamines and intrana-
sal steroids may provide adequate control of many aller-
gic problems, such as urticaria or intermittent rhinitis.
Immunotherapy
The use of allergen immunotherapy in the primary care
setting [166-169] and the use of allergen extracts for thediagnosis of allergic disease [170,171] have been well
documented. Before the mid-1980s many patients re-
ceived SCIT in the community setting. Skin prick testing
was used to assess patients before administration of aller-
gen extract solutions. Anecdotally, many of these patients
benefitted from this therapy, although it was delivered in a
haphazard, random fashion with no true systematic evalu-
ation. This resulted in a number of deaths and led to the
abandonment of immunotherapy in primary care, coupled
with a loss of confidence in this treatment modality, espe-
cially in the United Kingdom [172].
Recent research has shown that both SCIT [173,174]
and SLIT [175-180] are effective treatments for allergic
diseases. Given the significant burden these allergic dis-
eases impose on the health care system, AIT appears to
be a cost-effective adjunctive treatment in modifying the
existing disease state [61,181]. SLIT represents an effect-
ive and well-tolerated treatment for seasonal allergic
rhinoconjunctivitis in adults, but studies performed in
children in primary care have not yielded the same de-
gree of success as in adults for HDM allergy [53] or for
grass pollen allergy [182]. Current ongoing pediatric
trials and evaluation of long-term effects in adults will
further define its role in therapy [183], but there is evi-
dence that there is potential for early and significant cost
savings in children with allergic rhinitis treated with im-
munotherapy; thus, immunotherapy could significantly
reduce both allergic rhinitis–related morbidity and its
economic burden [184].
For the near future, some forms of immunotherapy
(e.g., Hymenoptera venom) will have to continue to be ad-
ministered in specialist units because of the risk of ana-
phylaxis. Nonetheless, SLIT offers an effective [185,186],
safe [86,187-189], and easy-to-use form of treatment that
can be administered in primary care [167,190-192]. Fatal
anaphylaxis to SLIT has not been documented, although
local side effects are relatively common [193].
Because patients self-administer SLIT at home, there is
considerable saving of time, both for the patient and of
the primary care team, who only have to supervise the
first dose, thus improving convenience and cost effect-
iveness for the patient [194-197].
There is now a wide range of allergens available for
SLIT, such as grass [198] and HDM [199-205], and evi-
dence for cumulative benefit is emerging [206,207]. Oral
immunotherapy to food allergens, especially peanut al-
lergens, is also a promising new use of this form of
therapy [208].
The current challenge is to identify those patients who
are most likely to benefit from the administration of
SLIT, including discovering the steps necessary to iden-
tify likely candidates, the investigations needed to valid-
ate that choice, and the mechanisms needed to ensure
efficient, effective, cost effective, and safe delivery of this
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of general practitioners who have a special interest in the
field of allergic disease diagnosis and management. This
new subgroup would receive a higher level of allergy train-
ing and would be provided with greater resources to as-
sess and investigate patient needs, especially when access
to allergy specialist care is difficult. Some title or creden-
tial would indicate that these GPs have reached level
higher in the field of allergy than would be the case for
most GPs [209]. For the immediate future, it would still be
advisable that the decision of whether or not to initiate
SLIT (as for SCIT) should be made by the allergist. The
average GP currently has limited knowledge concerning
SLIT [210].
Interested primary and secondary care organizations
should work towards developing a framework that will
lead to greater accessibility and availability of SLIT and
improved education of patients and providers alike.
Unmet needs
 Primary health care providers should learn to
differentiate between allergic disease and symptoms
with non-allergic causes such as respiratory viral in-
fections and common, pharmacologically mediated
reactions to foodstuffs, such as chilies and spices,
which cause a runny nose and watery eyes.
 PCP/GPs should be educated about the local
allergens in their areas of practice and their seasonal
prevalence. This may include seasonal airborne
allergens other than plant pollens.
 Primary health care clinicians should be able to use
readily available pharmaceutical agents to ameliorate
the symptoms of allergic rhinitis.
 Primary health clinicians, allergists, and other
specialists who treat allergy-related illnesses, such as
pulmonologists, otorhinolaryngologists, ophthalmol-
ogists, and dermatologists, should cooperate and
collaborate to plan preventive and therapeutic
measures.
 Primary health care clinicians need educational
initiatives to help them to understand
immunotherapy and, more importantly, to be able
to recognize which patients might benefit
from SLIT.
 Primary health care clinicians should collaborate
with their specialist colleagues to develop care
pathways to develop effective service delivery.
Chapter 10: Methodology of clinical trials
 Allergen immunotherapy (AIT) requires specifically
designed and sized trials that incorporate adequate
methodology and interpretation. Subjects included in AIT trials should have
experienced moderate to severe disease in
previous years.
 Strategies to guarantee adequate allergen exposures
and to avoid confounding factors require further
development and implementation.
 The risk of unblinding due to side effects requires
an analysis of the efficacy that takes into account
the incidence of side effects in both the AIT and
control groups.
 Standardized and validated primary endpoints that
properly assess symptoms and medication usage are
of paramount importance for improving the
comparability of study results.
 The validation of a clinical minimal difference of the
primary outcome and of a “responder” definition is
crucial to discriminate improvements in real-life
conditions.
 Secondary outcomes and surrogate markers do not
replace the primary endpoint and can only provide
additional information.
 Safety should be assessed using an universally
accepted system to grade and classify adverse events.
 Study duration should be based on the type of
efficacy being studied: treatment of allergic
symptoms, sustained clinical effect, long-term effi-
cacy and disease-modifying effect, or curative effect.
 Owing to variations in allergen content and
formulations between extracts, appropriate SLIT
dose-finding studies should be carried out for
each product.
 Allergen challenge chambers provide a promising
tool for evaluating the therapeutic effects of AIT in
phase 2 trials, but additional studies are needed for
comparison with natural pollen exposure.
 Large studies with standardized procedures
investigating short- and long-term protection against
food allergy, atopic dermatitis, and latex allergy
are needed.
 Better adherence to the CONSORT criteria is
needed to improve the quality of reporting of
AIT trials.Introduction
Quality of clinical trials
The use of appropriate methodology in randomized clin-
ical trials (RCTs) is essential for the critical assessment
and registration of therapeutic interventions. In a recent
study assessing reports of SLIT RCTs, only 4.2% met all
of the criteria of the CONSORT statement [211], al-
though a CONSORT statement checklist for conducting
and reporting trials in allergen immunotherapy (AIT)
has been published [212].
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Meta-analysis is a powerful tool for evaluating the effi-
cacy of a therapeutic intervention, and meta-analyses
have clearly demonstrated that AIT is effective overall
for treating allergic rhinitis and asthma [60]. However,
the methodological quality of systematic reviews of SLIT
could be improved by including more details about the
search strategy used, employing measures to avoid selec-
tion bias, assessing the methodological quality of the in-
cluded studies [213], increasing transparency on sources
of funding, and considering heterogeneity before pooling
data [214].
Differences in performing clinical trials for AIT and
pharmacotherapy
AIT and pharmacotherapy should be evaluated in separ-
ate, specifically designed RCTs. The results of AIT and
drug trials should not be directly compared, because the
characteristics of the studies and their settings are fun-
damentally different, including the severity and persist-
ence of allergic disease in the patients enrolled, the issue
of placebo, the allergen exposure, the level and severity
of symptoms of placebo-treated patients, the clinical
relevance of the efficacy of AIT, the need for validated
combined symptom-medication scores, the differences
between children and adults, and pharmaco-economic
analyses [215]. A major difference between clinical stud-
ies testing symptomatic medication and pollen AIT is
that symptomatic medication is evaluated during the
pollen season when patients have peak levels of symp-
toms, whereas AIT starts months before the beginning
of the pollen season, when patients are still asymptom-
atic and the intensity of the pollen season and the conse-
quent symptom level are unknown. Therefore, if the
intensity of the pollen season and the level of disease ac-
tivity is low for a subset of the patient population in AIT
studies, the efficacy of AIT can be underestimated, be-
cause a certain level of symptoms is necessary to dem-
onstrate the activity of any therapy. In addition, AIT
studies allow the use of rescue medication, further inter-
fering with the assessment [216]. These reasons explain
some of the low level of efficacy (20%–30% improvement
over placebo) seen in AIT RCTs as compared with medi-
cation RCTs when mean symptom-medication scores
are analyzed.
A joint effort between allergists, methodologists, regu-
lators, patient groups, and the allergen manufacturers to
address important research questions is desirable to ob-
tain answers as rapidly as possible [215].
Diseases and allergens to be investigated
Ongoing studies are evaluating the role of SLIT in food
allergy and oral allergy syndrome. SLIT studies specific-
ally for milk [135] and peanut [134,217] have shownclinical efficacy and safety. SLIT appears to be less effect-
ive, but also less burdened by side effects and systemic
reactions, than oral immunotherapy. Its short- and long-
term protection, however, remain to be determined in
larger controlled studies with standardized procedures
for allergen dosing, schedules, and duration [218].
In recent years, SLIT with inhalant allergens has been
used to treat oral allergic syndromes induced by foods
[219-221]. Larger and more rigorous studies are needed
to confirm its efficacy.
Although previous studies have suggested a possible
application of SLIT to atopic dermatitis in particular
subgroups of patients with specific disease severity and
sensitization profiles, the value of SLIT in atopic derma-
titis still remains unclear because of limited research in
this field, much of which has been of inadequate meth-
odological quality and has produced controversial find-
ings [222].
Further studies are needed to evaluate SLIT for latex
allergy. A recent prospective, observational, open, case-
control study provided encouraging results in children
[223], but was not confirmed in a randomized double-
blind placebo-controlled (RDBPC) trial in adults [224].
Quality and standardization of allergen vaccines
Although the standardization of allergen extracts is im-
portant for proper clinical dosing and efficacy, variability
in the biological potency of some allergen extracts has
been described [225].
Manufacturers in Europe have implemented extensive
protocols for standardization and quality control, but
each company uses its own in-house reference materials
and its own unique units to express potencies [226],
making the doses currently used for SLIT rather difficult
to evaluate. In addition, the potency of some European
allergen extracts differs markedly from standardized al-
lergenic extract preparations licensed in the US [227].
However, because the effectiveness of SLIT also depends
on additional factors apart from the exact dose (e.g.,
qualitative composition, presence of different adjuvant
molecules, bioavailability, route of administration), ap-
propriate SLIT dose-finding studies should be done for
each product [56].
The CREATE project has provided a major step for-
ward in allergen standardization and provides a model
for the development of a comprehensive panel of inter-
national reference preparations that will harmonize aller-
gen measurements worldwide [228].
Placebo
Appropriate placebos for SLIT are needed to preserve
the blinding of studies in the absence of local side ef-
fects, and any analysis of efficacy should take into ac-
count the incidence of side effects in both the SLIT and
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has been suggested as an alternative [215], wherein pa-
tients with dual sensitivities would be treated with active
SLIT for one and a placebo for the other.
The problem of unblinding of subjects due to side ef-
fects was raised to argue against the efficacy of SLIT ob-
served in recently concluded large clinical trials [229].
However, side effects were not infrequent in the placebo
groups, and the treatment effect was still clearly ob-
served when only groups with comparable local reac-
tions were compared [230]. An approach to verifying the
hypothesis of positive bias due to the patients’ recogni-
tion of the active treatment would be to assess the effect
of dose on the relationship between the occurrence or
frequency of side effects and the observed efficacy [231].
Finally, the placebo arm should be considered differ-
ently in AIT and allergy medication RCTs, because
placebo-controlled studies of SLIT permit free access to
usual anti-allergic drugs [215].
Selection of patients
There is a general perception of somewhat lower efficacy
results for AIT therapies compared with symptomatic
therapies, owing to some confounding factors such as
the inclusion of highly symptomatic patients and the
allowed use of reliever medications in AIT studies. How-
ever, the analysis of AIT studies shows higher clinical ef-
ficacy in highly symptomatic patients. A more accurate
comparison based on the high-symptom tertile from
AIT studies shows that the relative improvement in the
combined symptom score between active and placebo
groups ranged from 27% to 37% [216], beyond what is
normally reported for symptomatic treatments such as
antihistamines (7%) and nasal corticosteroids (18%) [232]
and the standard set for minimal clinically relevant effi-
cacy (20%) by a WAO task force [233].
Ideally, subjects included in AIT trials should have ex-
perienced moderate to severe disease in previous years
[215]. Registration studies should enroll patients who
are not taking regular medications for the treatment of
allergic diseases in order to assess the magnitude of the
treatment effect. However, other studies may be needed
to investigate whether AIT is effective in patients whose
allergies are not controlled by medications administered
at recommended doses. The concept of severe chronic
upper airway disease (SCUAD) has been proposed to in-
dicate patients whose allergic rhinitis is uncontrolled
despite adequate guideline-based pharmacologic treat-
ment [215].
Subtypes of allergic disease can be characterized in
terms of severity, activity, control, and responsiveness to
treatment, and these phenotypes can also be used to pre-
dict disease severity, progression, and response to treat-
ment. A uniform definition of severe allergic diseases isexpected to help in clinical practice, research and epi-
demiology, public health, education, registration of med-
icines and reimbursement, personalized medicine, and
the development of novel therapies [234].Design of clinical trials
Phase 2 studies
In past clinical experience, allergen doses were frequently
adapted to the individual patient; thus, there are few data
on the dose-response relationship of SLIT. Allergen prod-
ucts for SLIT are increasingly being required to conform
to regulatory requirements for human medicines, which
include the need to demonstrate dose-dependent effects.
A recent document, produced by a Task Force of the
EAACI Immunotherapy Interest Group, evaluated the
currently available data on dose-response relationships in
AIT and provided recommendations for the design of fu-
ture studies [56]. Evidence about dose-response effects on
efficacy and immunological outcomes is available from in-
dividual SLIT studies using native allergen extracts. Infor-
mation about the dose-response effect on safety will
benefit from future guidelines on the grading and report-
ing of adverse events, especially local reactions [235].
Owing to variations in allergen content and formula-
tions between products from individual manufacturers
and in the choice of endpoints, no comparison between
studies and general dosing recommendations can cur-
rently be made. As a consequence, SLIT preparations
should be studied individually in rigorous phase 2 dose-
finding studies, in parallel with studies using surrogate
antigen challenges in the eye and nose [235].
No definitive biomarkers predictive of a clinical re-
sponse to SLIT are currently available. Candidate markers
are facilitated allergen binding (FAB) inhibition, functional
assays of inhibitory IgG4 and IgE-blocking factor, and
basophil sensitivity [38,236], but further investigation is
required.Phase 3 studies
Baseline assessment Most large AIT RCTs require par-
ticipants to have had moderate to severe symptoms in
previous years. To achieve this, one approach would be
to start a 1-year placebo trial to select patients with suf-
ficiently severe disease for enrollment; however, pollen
seasons are highly variable between years and areas, and a
run-in period of 1 season before starting AIT is therefore
not feasible. Patients’ medical allergy history data are used
in most RCTs, but they may not be reliable, because pa-
tients are likely to recall the most severe symptoms but
not the average symptoms from the previous season.
Nonetheless, many studies have found that the major-
ity of patients consulting allergy practices have moderate
to severe intermittent or persistent rhinitis, and thus it is
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specialists have moderate to severe symptoms [215].
Randomized clinical trials in rhinoconjunctivitis As-
sessment of Allergen Exposure. The level of pollen ex-
posure should be taken into account when interpreting
symptom scores in studies of AIT to treat pollen allergies.
There is controversy about the correlation between pollen
counts and the degree of clinical symptoms, with some
studies showing a relationship [237,238] and others failing
to show a connection [239]. The missing correlation may
be due to numerous factors, including variations in aller-
gen potency, weather changes such as rain, the presence
of pollens outside of the pollen season, patients traveling
in and out of pollen areas, heterogeneous pollen sampling
and definitions of the pollen interval or threshold, and
simultaneous exposure to other aeroallergens and irri-
tants. Confounding elements that can affect clinical symp-
toms due to house dust mites are polysensitization, in
particular to pets, and allergen avoidance measures be-
cause, although not clearly effective, they may be benefi-
cial to some subjects [215,240-242].
In addition, the number of pollen grains needed to
elicit symptoms is not well defined; therefore, a priori
exclusion of centers in which the level of pollen is too
low is not an acceptable approach. Using individual sam-
plers to measure pollen and evaluating the effect of AIT
relative to these measurements may solve this problem
[243], although this goal will be difficult to achieve.
The definition of a peak season based on symptom/
medication scores of the placebo group rather than on
pollen counts (“peak placebo symptom days”) has also
been proposed as an innovative approach to the analysis
of seasonal diaries after AIT [244,245]. This approach al-
lows the local allergy burden to be determined at differ-
ent centers and seems applicable for prospective and
retrospective studies, but its use remains to be validated.
Phenology and the biomolecular identification of aller-
genic pollen may represent a new perspective for future
aerobiological monitoring [215,246]. For indoor aller-
gens, the assessments of allergen exposure by measuring
major allergens in reservoir dust samples (bed, carpet, soft
furnishings, and so forth) using monoclonal antibody–
based enzyme-linked immunosorbent assays might pro-
vide levels of individual exposure [226].
Primary Outcome Parameters. Standardized and vali-
dated primary endpoints are of paramount importance
to improving the comparability of study results. In real
life, patients receive both SLIT and medications to opti-
mally control symptoms. In clinical studies, the prohib-
ition of rescue medication is unethical because the pollen
season may be long and intense. Older studies often used
the total symptom score and the total medication score
individually for the primary efficacy analysis. Because theintake of rescue medication interferes with the assessment
of symptom scores, the Committee for Medicinal Prod-
ucts for Human Use of the European Medicines Agency
(EMA) has recommended the use of combined symp-
tom–medication scores but has not specified a recom-
mended instrument [247]. Different algorithms have been
developed for calculating adjusted symptoms +medication
scores, but none is universally accepted and to date only
one has been standardized and formally validated by tak-
ing into account the global allergy severity, allergy-related
consultations, and the (also validated) rhinitis quality of
life to produce an “allergy control score” [248]. Another
possible approach, described in detail in 2 post-hoc ana-
lyses, is the “adjusted symptom score,” which adjusts the
symptoms according to the use of medication by calculat-
ing the last observation carried forward [136].
A validated clinical minimal difference of the primary
outcome parameters in RCTs is still an unmet need
[215]. The decrease in symptom scores should be high
enough to clearly reduce allergy-related morbidity under
“real life” conditions [215]. Beyond the statistical signifi-
cance of changes emphasized by many trials, the clinical
relevance of the studies lies in the ability of patients to
discriminate between treatments that are and are not ef-
fective [215]. The 20% relative improvement with respect
to placebo proposed by WAO addresses this issue [233].
A further approach based on a “modified responder ana-
lysis” found that a cutoff of 30% optimally discriminated
between active and placebo treatments during the entire
season [249].
Secondary outcome parameters. A wide range of
secondary outcomes are used in clinical trials, but few are
validated or standardized. They include individual symp-
toms, quality of life and patient-reported outcomes
[250,251], visual analog scales, and symptom-free or “well
days” (described by EMA as “days without intake of rescue
medication and a symptom score below a predefined and
clinically justified threshold”) [252]. The item “days with
severe symptoms” (or worst days) has recently been intro-
duced to describe the treatment effect on the most
troublesome days in the pollen season [253].
Functional measures (conjunctival, bronchial, or nasal
provocation tests; acoustic rhinometry; spirometry; and
peak expiratory flow rate) and in vitro parameters (aller-
gen-specific IgE and specific IgG levels) are useful to
support the primary clinical outcome [252], but second-
ary outcomes and surrogate markers do not replace
the primary endpoint and can only provide additional
information.
Exploratory outcome parameters. Provocation tests (e.g.,
conjunctival, nasal, or bronchial provocation or allergen
exposure in allergen challenge chambers) may be used as
primary endpoints in early-stage, dose-ranging (phase 2)
studies [247].
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and used in many studies. Allergen challenge chambers
provide a promising tool for evaluating the therapeutic ef-
fects of AIT. This method overcomes some drawbacks of
conventional clinical outdoor studies, such as the unpre-
dictable levels of pollen, and facilitates both a controlled
and reproducible pollen challenge using a predefined
protocol, with acceptable sensitivity and specificity in the
reproduction of outdoor conditions [19,43,254,255]. This
technique has been largely used in studies with drugs, and
single challenge tests cannot imitate the priming effect of
repeated or continuous allergen exposures seen in real life,
which are needed to test AIT. The provocation in allergen
chambers might be a helpful substitute, especially in long-
term studies over several years, for a pollen season with
low pollen counts in which an evaluation of the response
to natural exposure is not possible [247]. However, add-
itional studies are needed to validate allergen challenge
chambers more thoroughly compared to natural pollen
exposure [19,256-258].
Reliable predictive surrogate markers or biomarkers
are needed that correlate with real clinical endpoints
and could lead to individually tailored immunotherapy
treatment. Potential surrogate markers could include
early and late skin reactions as well as immunological
parameters such as IgE levels, IgG subclasses, mucosal
IgA, lymphocyte subsets, cytokines, and local and sys-
temic inflammatory markers, but most markers have
had low reproducibility and poor correlation with the
clinical outcome in clinical studies. Combined with the
low availability of assays for these markers in daily prac-
tice and anticipated high costs, these results mean that
further investigation is needed to identify an ideal surro-
gate marker [259].
Study duration. In SLIT trials, induction and mainten-
ance schedules varied widely in dosing interval, treatment
duration, and whether treatments were administered pre-
seasonally, pre-coseasonally, or perennially. The optimal
duration has not been investigated in clinical studies, but
the main aim of AIT is a persistent effect due to changes
in the immune system that can only be demonstrated in
long-term studies. High-dose grass pollen SLIT has been
shown to have a sustained effect [3,260], and 3 years of
treatment provides a beneficial effect that lasts for a fur-
ther 2 years after stopping treatment [4,120,261].
In general, according to the EMA [247], different
claims for efficacy are possible depending on study dur-
ation. These include treatment of allergic symptoms
(short-term clinical trials conducted to show efficacy in
the first pollen season after start of AIT or to show effi-
cacy in perennial allergies after some months of treat-
ment), sustained clinical effect (maintenance of significant
and clinically relevant efficacy during 2 to 3 treatment
years), long-term efficacy and disease-modifying effect(sustained significant and clinically relevant efficacy in
post-treatment years), and cure (sustained absence of
allergic symptoms in post-treatment years). Long-term
studies can also be planned to document effects on
the prevention of asthma and the spread of sensitization.
Studies intended to address more than one claim
must be carefully preplanned to avoid methodological
problems.
Adherence to immunotherapy. Adherence to prescrip-
tions is crucial for all long-term treatments, and this is
particularly true for SLIT, which is managed at home by
the patients themselves. Available postmarketing studies
indicate that the compliance with SLIT ranges from 50%
to 95%, depending on age and on duration of treatment
[262]. Nonetheless, these reports have an inherent limita-
tion in that the observation itself can distort the results to
some extent. Sales data provided by manufacturers show
an alarming rate of SLIT discontinuation, approximately
90% at 3 years after the prescription is first written [263].
However, a German analysis of renewal prescription for
SLIT showed that after 2 years 51% of subjects had at
least one renewal prescription, which is partially re-
assuring [264].
The major issues influencing patient adherence to
SLIT are thought to be the patient’s perception of clin-
ical efficacy, cost, and side effects [265,266]. Among the
reasons cited for discontinuing treatment, SLIT patients
indicated efficacy concerns as the major basis for with-
drawal [267]. Improvement of adherence is likely to be
achieved by improving the patient information provided
by prescribers [266,268,269] and reducing the interval
between follow-up visits [269,270].
Publication of the results. As in other areas of medi-
cine, the quality of reporting of most immunotherapy
trials is low. According to a recent review, only 4.2% of
SLIT RCTs met all the criteria of the CONSORT State-
ment, suggesting that the use of the CONSORT State-
ment should be further encouraged [211].
Randomized clinical trials in asthma
Studies in Children Because AIT has an indication for
treatment of children, AIT products should be tested for
efficacy and safety in pediatric populations [247]. How-
ever, this is a vulnerable population with specific issues
concerning the recording of symptoms, the use of rescue
medications, safety, and acceptance, especially in very
young patients. The efficacy of products for SLIT there-
fore has to be evaluated in special trials in the pediatric
population and not in combined trials of children and
adults or derived from extrapolations [247].
In Europe, a demonstration of long-term efficacy is
required for the pediatric investigation plan (PIP) that
must accompany applications for marketing authorization
submitted to the EMA [235]. Although this approach is
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several years at an age when active AIT might be most
effective, raising concerns about the ethics of such a strat-
egy, as well as the feasibility [271].
In recent years, large RDBPC trials conducted in
Europe [54,124,125] and the US [40] with grass pollen
SLIT demonstrated efficacy and immunological effects
in children and adolescents during the first treatment
seasons, and safety was acceptable. The pediatric popu-
lation is expected to best benefit from the preventive
effects of AIT, leading to the question of when to start
treatment to achieve maximum efficacy. SCIT has a rela-
tive contraindication in children less than 5 years of age
because of the possible severity of adverse effects, but
SLIT may have a better safety profile, as documented by
post-marketing surveillance safety studies conducted in
children under the age of 5 [104-107].
For all these reasons, more priority should be given to
the development of studies on primary and secondary
prevention using AIT.
Prevention studies Allergic rhinoconjunctivitis is a risk
factor for the development of asthma, and treatment of
the underlying allergy may represent an attractive method
of asthma prevention, mainly in the pediatric population.
However, no regulatory guidance exists in this area.
An ongoing multinational RDBPC trial in 5- to 12-year-
old children was first designed to assess the preventive
effect of high-dose grass SLIT on asthma development,
both during treatment and after the end of treatment
[119]. A randomized multinational trial conducted by the
Immune Tolerance Network is investigating the potential
role of SLIT in the primary prevention of aeroallergen
sensitization and asthma in children with atopic dermatitis
at risk for developing asthma and atopy [119,272]. The
outcomes of these preventive intervention studies will
provide evidence as to whether or not SLIT can play a role
in the primary or secondary prevention of atopic diseases.
Cost-effectiveness studies The cost-effectiveness of im-
munotherapy depends on the duration of the clinical
benefit of immunotherapy following treatment cessation
and on the break-even point of cumulative costs be-
tween immunotherapy and pharmacotherapy [273].
For SLIT with grass pollen allergens, short- and medium-
term effectiveness can be regarded as proven, as long as the
indication is appropriate and no contraindications are
present. With other seasonal allergens, such as tree pollen
allergens, it can be an effective treatment option, but data
are rather scarce. No consistent proof of effectiveness is
available for SLIT with house dust mite allergens and other
perennial allergens [274].
To provide definitive evidence of cost-effectiveness,
there is a need for health economic studies based on high-quality prospective and long-term clinical studies compar-
ing immunotherapy with pharmacotherapy in real-life
practice and comparing SLIT with SCIT [273,275].
Chapter 11: Guideline development: from
evidence-based medicine to patients' views
 Guidelines should be evidence-based and lately
also safety, patient preference and costs are
taken into account in the development of
recommendations.
 Local guidelines on allergen immunotherapy have
now been developed in several different countries/
regions of the world. Their content is briefly
reviewed in this chapter.
 Immunotherapy –sublingual and subcutaneous- has
been included as one of the treatment options in
several guidelines on the management of allergic dis-
eases (rhinitis, asthma, etc.)
 There are progressively more systematic reviews on
sublingual immunotherapy that sustain guideline
recommendations
 The quality of the manuscripts reporting clinical
trials on which sublingual immunotherapy
guidelines are based can still be improved, e.g. taking
into account the CONSORT criteria.
Evidence-based medicine has become an essential com-
ponent in the preparation of guidelines, in that it attempts
to provide a logical, transparent, and applicable framework
from which the quality and relevance of clinical studies
may be assessed in an unbiased manner [276]. However, it
has become clear that factors other than scientific evi-
dence should contribute to recommendations in favor of
or against certain actions in the medical treatment of
patients. In the course of the past decade, new systems
for guideline development and evaluation have been de-
veloped, including the Grading of Recommendations
Assessment, Development, and Evaluation (GRADE)
system [277].
The GRADE tool has been introduced as a method to
support the use of clinical recommendations derived
from analyses of different aspects of medical treatment
in health policy decision making (Figure 4). Quality evi-
dence from published research forms the basis of the
guidelines, but safety, cost, and patients’ preferences are
all considered in making the final recommendations.
Tools to define the scientific quality of clinical trials that
take into account internal and external validation and
the risk of bias form an integral part of the GRADE sys-
tem. In GRADE, all clinical trials—irrespective of their
design—are considered, and their quality of evidence is
established according to defined parameters (Table 9)
[126]. Since 2004, the GRADE system has been adopted
Figure 4 The GRADE system: from clinical question to
recommendation.
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Guidelines on immunotherapy
Since the publication of the original WAO sublingual
immunotherapy (SLIT) paper [9], several new guidelines
on allergen immunotherapy (AIT) have been published
in which SLIT has been taken into account. Some of
these new guidelines have adopted the GRADE system
and its evidence model, whereas others have kept the
Shekelle system (Table 9).
The Canadian Society generated a consensus paper on
immunotherapy in 2006 [285] that evaluated SLIT posi-
tively as a novel form of allergen administration, but no
clear recommendation was given. Similarly, the American
Practice Parameters on Immunotherapy, 3rd update [102],
reviewed SLIT positively, but gave no recommendations
for its use in the United States (US) because there is still
no Food and Drug Administration–approved product on
the US market. Even so, some US physicians do apply
SLIT using the subcutaneous immunotherapy (SCIT)
concentrated extracts to prepare the vials [296-298]. An
expert panel of US allergists concluded that approved
SLIT extracts will probably be on the US market in the
near future, which should improve access to allergen im-
munotherapy for American allergy sufferers. However, the
panel also raised some questions concerning how the effi-
cacy/safety profile of SLIT compares to that of SCIT and
how applicable a single grass allergen tablet will be in
treating polysensitized patients, who represent the major-
ity of individuals undergoing SCIT in the US [299].
The Argentinean Guidelines on Allergen Immunother-
apy for the Prevention and Treatment of RespiratoryAllergy in Childhood [286] analyze immunotherapy in
general and include a table with grade of evidence and
level of recommendation taken from other guidelines,
without a specific new review of the literature. They rec-
ommend immunotherapy for allergic rhinitis, allergic con-
junctivitis, and asthma as cotreatment with medication.
The guidelines make a special note that SLIT is indicated
in children who do not tolerate or accept injections.
The British guidelines on immunotherapy for allergic
rhinitis state that both SCIT and SLIT are effective treat-
ments for adults and children with severe allergic rhinitis
who have failed to achieve sufficient relief of symptoms
despite adequate medical treatment with antihistamines
and intranasal corticosteroids and allergen avoidance. The
guidelines conclude that there is category 1a evidence, ac-
cording to Scottish Intercollegiate Guidelines Network
(SIGN) grading for efficacy (www.sign.ac.uk/) in both
adults and children and that the evidence is particularly
strong for seasonal pollinosis. British experts state that
SCIT and SLIT have been shown to give long-lasting
benefit for some years after treatment is stopped. How-
ever, for asthmatic patients the risk/benefit balance is less
favorable than for patients with rhinitis, and therefore im-
munotherapy for asthma is not routinely recommended in
the United Kingdom. Further, the guideline states that the
safety profile of SLIT appears to be superior to that of
SCIT [287].
The Mexican guidelines include an in-depth analysis
of the literature following the GRADE system. SLIT is
recommended as an alternative to SCIT in children and
adults with allergic rhinitis and/or asthma in whom AIT
with pollen and/or house dust mite (HDM) is indicated,
but who reject injection treatment or in whom there
might be safety issues with SCIT. In Mexico, SLIT is grad-
ually updosed over at least a month’s time. SLIT is also
suggested for selected patients with atopic dermatitis and
aeroallergen sensitization, latex allergy, or large local reac-
tions secondary to Hymenoptera venom allergy [288].
The Subspecialty Group of Rhinology of the Chinese
Society of Otorhinolaryngology Head, Neck Surgery that
is part of the Chinese Medical Association wrote an ex-
pert consensus on AIT for allergic rhinitis [289]. As the
full text is in Chinese we could not analyze the exact
content of this document.
Other guidelines in which immunotherapy is mentioned
There are several other related guidelines in which rec-
ommendations for immunotherapy are mentioned, al-
though not all specify the sublingual route. The updated
version of ARIA 2010 [292] includes the GRADE system
for evaluation of the evidence. ARIA 2010 ‘suggests’
(that is, weakly recommends) the use of SLIT in adults
with allergic rhinitis without asthma caused by pollen or
HDM allergy and in children with allergic rhinitis caused
Table 9 Evidence models used to establish guidelines for sublingual immunotherapy
Year Evidence model No. of RCTs* Recommendation
Specific guidelines on immunotherapy**
WHO consensus [278] 1989 None 0 None
EAACI 1988 guidelines [279] 1988 None 0 None
EAACI 1992 [280] 1992 None 0 None
WHO Position Paper [281] 1998 None 2 None
EAACI Local 1998 None 4 Suggested in adults
Immunotherapy [282]
AAAAI/ACAAI Practice parameters
[283]
2007 Shekelle [284] 14 SLIT as investigational in US (no FDA
approval yet)
Canadian guidelines [285] 2006 None 10 SLIT evaluated positively as ‘novel form’, but
no recommendation given
Argentinean guidelines [286] 2010 None† No review Indications on IT in general (AR, AC,
Asthma) as co-treatment with medication.
Extra indication for SLIT if SCIT is not toler-
ated/acceptable
AAAAI/ACAAI Practice parameters
[102]
2011 Shekelle [284] 9 SLIT as investigational in US (No FDA
approval yet)
British guidelines [287] 2011 SIGN 25 SLIT for adults and children with AR, after
treatment failure with medication and
avoidance.
Mexican guidelines [288] 2011 GRADE 18 Recommend SLIT for adults and children
with AR and asthma; suggest for some cases
of atopic dermatitis, latex allergy, and large
local reactions to hymenoptera venom.
Chinese expert consensus on AIT
for AR [289]
2011 Consensus ? ?
Finnish update on current care
guidelines: AIT [290]
2012 ? ? Indicated for AR caused by grass pollen.
Oral tolerance induction in children older
than 5 y with severe food allergy.
Other guidelines in which immunotherapy is mentioned
ARIA 2001 [291] 2001 Shekelle [284] 12 Recommended in adults, suggested in children
ARIA Update 2008 [159] 2008 Shekelle [284] 36 Indicated in the same conditions as SCIT:
patients with rhinitis/conjunctivitis/asthma
caused by pollen or HDM; patients who have
presented systemic reactions during SCIT.
ARIA Update 2010 [292] 2010 GRADE 63 Suggests the use of pollen and HDM SLIT
for allergic rhinitis in adults and of pollen
SLIT in children. Does not suggest HDM SLIT
in children for treatment of AR. Suggests
SLIT in patients with AR+Asthma for asthma
treatment (low quality evidence).
GA2 LEN/EAACI pocket guide for
AIT [293]
2010 Based on WAO IT
papers and ARIA
2001, 2008, and 2010
No new review
BSACI guidelines on Hymenoptera
venom allergy [294]
2011 NICE accredited 0 SLIT for venom immunotherapy is
mentioned as a future research area.
Guidelines for treatment of atopic
eczema of the European Academy
of Dermatology and Venereology
[295]
2012 Appraisal of Guidelines
Research and Evaluation
and DELPHI procedure.
0 (this is a Review of
Guidelines not RCTs)
Allergen IT (not stating SLIT or SCIT) to
aeroallergens may be useful in selected
cases of atopic eczema.
*number of randomized controlled trials on SLIT the guidelines are based on.
**normal font: published in the original WAO SLIT position paper; bold font: new guidelines published since 2009.
†Table of evidence and recommendation taken from other guidelines based on Shekelle [284].
AC = allergic conjunctivitis; AIT, allergen specific immunotherapy; AR, allergic rhinitis; FDA, US Food and Drug Administration; HDM, house dust mite; IT,
immunotherapy; NICE = National institute for Health and Care excellence, RCT, randomized controlled trial; SIGN = Scottish Intercollegiate Guidelines Network
(SIGN) (www.sign.ac.uk/); SLIT, sublingual immunotherapy.
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2010 suggests that SLIT should be part of the integral
treatment of the asthma. ARIA 2010 is based on publica-
tions up until 2009 and inevitably lacks the inclusion of
several recent high-quality SLIT trials, which are likely
to influence the next update.
The GA2 LEN/EAACI Pocket Guide for Allergen Im-
munotherapy for Allergic Rhinitis and Asthma [293]
quotes the WAO and ARIA guidelines. It recommends
considering AIT in patients with moderate to severe
intermittent or persistent allergic rhinitis and in mild
(controlled) allergic asthma proven to be caused by a
well-defined allergen; it particularly recommends AIT
in those who do not respond sufficiently to current phar-
macological treatment. These guidelines state that in-
dependent studies show that both SCIT and SLIT are
effective in allergic rhinitis and asthma if optimally used.
Other guidelines in which immunotherapy is mentioned
are the British Society for Allergy and Clinical Immun-
ology (BSACI) guidelines on Hymenoptera venom allergy
[294] and the guidelines for treatment of atopic eczema of
the European Academy of Dermatology and Venereology
[295] (Table 9).
Italian investigators studied the congruence between
international guidelines and AIT prescription patterns in
518 patients from 34 allergy centers. The investigation
focused on the fact that ARIA and GINA guidelines rec-
ommend prescribing AIT according to disease severity.
They concluded that in mite-allergic patients with rhin-
itis and asthma comorbidity, the severity of rhinitis and
young age are the most important factors driving AIT
prescriptions. The congruence of AIT prescriptions with
guidelines was better for the ARIA (r = 0.87; P = 0.001)
than for the GINA (P = 0.02) guidelines [300].
Quality of SLIT meta-analyses and clinical trials
The 3 types of scientific sources used to develop the
guidelines reviewed above are other guidelines, systematic
reviews, and clinical trials. Although systematic reviews
are considered one of the main pillars of evidence-based
medicine, it has become clear that systematic reviews can
be of varying quality, depending on the quality of the in-
cluded trials and the rigor of the analytical method used.
Cochrane meta-analyses, conducted under the auspices of
the Cochrane Collaboration Group, must meet the highest
quality standards. An updated Cochrane meta-analysis on
SLIT for allergic rhinitis published by Radulovic et al. in
2011 included 42 randomized, double-blind, placebo-
controlled trials. It showed that SLIT significantly reduced
rhinitis symptoms and medication requirements [1].
The quality of the published manuscripts from clinical
trials on allergen immunotherapy is not always optimal,
as shown in a CONSORT analysis of publications on
SCIT and SLIT trials [211]. Only a small percentage ofSLIT trials met all CONSORT criteria. Because this is a
tool for evaluating published data, it does not necessarily
indicate poor quality of the trials themselves, but it does
demonstrate that there is a need for improved quality of
published documents. To facilitate this task, a CON-
SORT statement checklist in allergen-specific immuno-
therapy has been published [212].
Conclusions and future needs
Since the publication of the original WAO SLIT paper
[9], several new guidelines that focus on allergen im-
munotherapy have been published, as have guidelines
that include statements concerning allergen immuno-
therapy. All reviews support the use of SLIT for treat-
ment of seasonal allergic rhinitis in adults and children,
whereas for perennial HDM allergy and in patients with
bronchial asthma the data on SLIT efficacy are judged to
be less robust. The majority of guidelines recognize SLIT
to be safer than SCIT. However, there are 6 reports
worldwide of severe systemic reactions to SLIT. Because
SLIT is administered at home, patients should be edu-
cated on how to recognize and treat systemic reactions.
Two recent, long-term, large randomized controlled
trials have provided evidence for the persistent long-
term effect of SLIT for at least 1 [120] and 2 [4] years
following its discontinuation. The possible preventive ef-
fect of SLIT on the development of asthma in children
with allergic rhinitis is the primary aim of a large double-
blind placebo-controlled study currently in progress (the
GAP study) [119].
Systematic reviews and meta-analyses continue to rep-
resent the most robust forms of scientific evidence for
efficacy, but they do have limitations. For example, sys-
tematic reviews are based on clinical trials that recruit
highly selected patients, so that extrapolation to the
whole allergic population may not always be justified.
There is also the potential problem of negative selection
bias in the published evidence and the potential for lack
of complete reporting of harmful effects, which may skew
the results of subsequent analyses. The recent evolution of
‘definitive,’ adequately powered, multicenter randomized
controlled trials in both children and adults should
minimize these concerns. Furthermore, both the European
and American Academies of Allergy, Asthma, and Im-
munology have established surveillance studies of AIT to
be completed by their members [71,301]. Data obtained in
these real-life situations will be important for improving
decision making for further guideline development.
Unmet needs
 Immunotherapy guidelines should be based on
up-to-date internationally recognized tools such as
GRADE (Grading of Recommendations Assessment,
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collegiate Guidelines Network), or NICE (= National
institute for Health and Care excellence) to make
them more robust.
 Recommendations given in immunotherapy
guidelines should differentiate between and for
different allergic diseases, adults versus children,
and –in some cases- different allergen groups.
 It is of importance to make the latest evidence of
SLIT more visible and accessible, so
recommendations on the use of SLIT in Guidelines
on the management of related allergic diseases can
be based on the latest data.
 To adjust recommendations on SLIT use in
Guidelines properly conducted studies on its effects
on disease progression and prevention are crucial.
 A recently published standardized reporting system
for local side effects associated with SLIT [76]
should be used in future clinical trials, so results are
more uniform and can be used for issuing the safety
part of guidelines.
Chapter 12: Practical aspects of schedules and
dosages and counseling for adherence
 Extracts supplied by different manufacturers are still
quantified by in-house reference materials with
different (manufacturer-specific) units. As a
consequence, a comparison of the potency of
different allergy immunotherapy (AIT) products
is not feasible.
 Standardization of materials and methods for
determining the major allergen content of different
AIT products would be preferable. A first approach
in this direction has been made by the European
Academy of Allergy and Clinical Immunology
(EAACI) “CREATE” project.
 Adherence to sublingual immunotherapy (SLIT) is
crucial for the effect size of this therapy. Real-life
data from the SLIT European market reveal low
levels of adherence.
 There is a clear need for improving adherence by
systematically addressing it and its determinants and
by putting more effort into educating patients,
general practitioners (GPs), and specialists.
Dosages
Although sublingual immunotherapy (SLIT) was first in-
vestigated more than 25 years ago in a double-blind
placebo-controlled clinical trial [302], extracts supplied by
different manufacturers for this (causal) therapy are still
quantified by in-house reference materials with different
manufacturer-specific units, such as “therapeutic units”
(TU), “allergen units” (AU), and “index of reactivity” (IR)[303,304]. This makes it difficult or impossible for the pre-
scribing allergist to compare different SLIT products with
regard to the potency.
A review article by Larenas-Linnemann et al. summa-
rized all available information as provided by the manu-
facturers on the monthly maintenance doses of different
SLIT products [303]. The authors reported that these
doses were 5 to 45 times higher than the doses for sub-
cutaneous immunotherapy (SCIT) products from the
same manufacturers. However, it was not possible to com-
pare different SLIT products, because heterogeneity was
found in the major allergen extracts of different products
as well as in the enzyme-linked-immunosorbent assays
(ELISAs) and antibody sera used for reference extracts.
This led the authors to conclude that the “effective dose
range [for SLIT] still is to be determined” [303].
As a consequence, it would be advisable to have stan-
dardized materials and methods for determining the aller-
gen content of different SLIT products. A first approach
in this direction has been made by the CREATE project
for the development of certified reference materials for al-
lergenic products and validation of methods for their
quantification, which was initiated by the EAACI in the
last decade [226,228]. The initial aim was to establish and
validate assays and corresponding monoclonal (recombin-
ant) antibodies for the quantification of the 2 most preva-
lent allergens, Bet v 1 and Phl p 5, in diagnostic and
therapeutic extracts. Since then, this project has been
pursued by the European Directorate for the Quality of
Medicine & HealthCare (EDQM, http://www.edqm.eu).
In November 2011, EDQM published valid data for the
in vitro quantification of Bet v 1 in different extracts
with the aim of having the European Pharmacopoeia
adopt the assays and reference materials, which will be-
come a reliable option for quantifying (and comparing)
extracts in the near future.
Amount of Phl p 5 and Bet v 1 allergens in SLIT products
In 2007, Sander et al. [304] investigated the daily amount
of the major allergen Phl p 5 in 10 different grass pollen
extracts produced by different European manufacturers
by using validated ELISAs (Bradford assays, inhibition of
IgE binding to Phleum pratense ImmunoCaps, and con-
tent of the main allergen by 2-site enzyme immunoas-
says). The authors concluded that the Phl p 5 content in
daily doses of the SLIT products ranged from 0.2 to
21.6 μg in the extracts investigated (reviewed in [305];
Table 10).
In 2009, the extracts were reanalyzed by the same
working group [306]. In between, the amount of major
allergen in 2 liquid SLIT products was modified, and 1
grass-pollen tablet product was measured for the first
time because it had not been on the market at the time
of the first analysis 2 years earlier. Some SLIT products
Table 10 Daily doses of Phl p 5 in different SLIT
preparations*
Manufacturer** Brand
(concentration)
Daily doses of
Phl p 5 (μg),
analysis of
Sander et al.
2009 [304]
Daily doses of
Phl p 5 (μg),
analysis of van
den Hout et al.
2010 [306]
Allergopharma Allerslit forte 21.6 n.d.
(715 000 SE/mL)
Allergy-
Therapeutics
Oralvac plus 0.6 n.d.
(768 000 TU/mL)
ALK-Abello Grazax 5.0 5.0
(75 000 SQ-T)
ALK-Abello SLIT one 0.2 1.4
(1 000 STU/mL) (SLIT one plus:
2 500 STU/mL)
ARTU Biologicals Igevac 7.8 n.d.
(9 500 BE/mL)
HAL Allergy Sublivac B.E.S.T. 3.6 6.2
(10 000 AU/mL) (Sublivac FIX:
10 000 AUN/mL)
Immunotek Sulgen 0.9 n.d.
(30 000 TU/mL)
Laboratorios LETI Tol SL 0.2 0.2
(100 HEPL/mL)
Stallergenes Staloral 300 8.4 n.d.
(300 IR/mL)
Stallergenes Oralair (300 IR) n.d. 5.2
*Modified with permission from [304-306].
**Manufacturers are listed in alphabetic order.
HEPL, histamine equivalent prick leti; STU, standard treatment units; TU,
therapeutic units; AU, allergen units; BE, biologische Einheiten; IR, index of
reactivity; SQ-T, standardized quality units tablet; SE, sublinguale Einheiten;
AUN, Allergy Units Native; n.d., not determined.
Table 11 Daily doses of Bet v 1 in 4 SLIT preparations*
Manufacturer** Brand
(concentration)
Daily doses of Bet v 1 (μg),
analysis of Kerkvliet et al.
2011 [307]
ALK-Abello SLIT one plus 5.8
(2 500 STU/mL)
HAL Allergy Sublivac FIX 46.7
(10 000 AUN/mL)
Laboratorios LETI TOL SL 1.0
(100 HEPL/mL)
Stallergenes Staloral 25.4
(300 IR/mL)
*Modified with permission from [305,307].
**Manufacturers are listed in alphabetic order.
HEPL, histamine equivalent prick leti; STU, standard treatment units; IR, index
of reactivity; AUN, Allergy Units Native.
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cluded in the analysis. Importantly, the measured doses
for all SLIT products were below the amounts published
by manufacturers from their in-house assays [305].
The daily amount of the major allergen Bet v 1 in 4
birch SLIT products has been also analyzed ([307],
reviewed in [305]; Table 11). The authors concluded that
the Bet v 1 amount in the daily doses of investigated
SLIT products ranged from 1.0 to 46.7 μg in the extracts
investigated.
Taken together, these heterogeneous data underline the
importance of establishing standardized methods to evalu-
ate the major allergen contents in different SLIT products,
as proposed by the EDQM. This approach would make
feasible a direct comparison of different SLIT products.
However, one should keep in mind that using monoclonal
“marker” antibodies would only give information on the
corresponding major allergen in SLIT preparations. Inproducts such as grass-pollen extracts with multiple dom-
inating major allergens, information on the content of
only one “marker” allergen, such as Phl p 5, would be feas-
ible, which would, again, make it difficult to compare SLIT
products.
Dosing schedules for SLIT products on the market
The SLIT products on the market are accompanied by a
high variety of recommendations on when treatment
should begin and schedules regarding the updosing and
maintenance phases (Table 12).
Counseling for adherence
As for every chronic condition, adherence to the treat-
ment is a critical issue. Rates of adherence in individual
patients are usually reported as the percentage of the
prescribed doses of medication actually taken over a spe-
cified period [310]. There is no consensus standard on
what represents an acceptable adherence rate (which
should, in principle, be 100%); however, as a convention
it is considered that adherence greater than 80% is ad-
equate for most treatments [310]. Several methods have
been employed for measuring adherence, but none of
them can be assumed as the gold standard.
So far, 6 observational studies have specifically ad-
dressed this issue [75,311-315]. Overall, 1879 patients
were evaluated (848 adults, 154 adolescents, and 877 chil-
dren). The follow-up duration ranged from 3 months to
3 years, and the average adherence was around 80%. In
the so-called “big trials”, which involved more than 150
patients and were mainly performed to assess the clinical
efficacy and safety of dissolving tablets, the adherence was
reported to be around 90% (range 88%–94%) in both
adults and children [183]. Although controlled studies and
real life represent different situations, the evaluation of ad-
herence in large trials can be taken as a useful model to
predict the potential drawbacks of treatment in real life.
Table 12 Specific characteristics of some SLIT products on the market*
Manufacturer Brand Initiation of therapy Length of induction phase to
reach maintenance dose
Maintenance therapy
Allergopharma
(manufacturer)
InfectoSlit Gräser
(formerly
distributed and
marketed as
Allerslit forte)
Preseasonal start of SLIT is
recommended, then perennial
therapy
Updosing on 1st day under
guidance of physician
4 drops daily, approximately 3
minutes before swallowing,
thereafter 30 minutes no drinking
or eatingInfectoPharm
(distributor)
ALK-Abelló SLIToneULTRA Perennial start possible SLIToneULTRA is provided in
single-dose containers. Induction
phase duration 5–10 days. Start
with 50 SRU (Standardized Re-
activity Units) for 5 days. Mainten-
ance dose is 100 SRU, 150 SRU, or
300 SRU.
0.5 mL (one single-dose container)
daily.
Perennial intake.
ALK-Abelló GRAZAX Perennial start possible. No updosing phase needed, Start
with maintenance dose, first
intake under guidance of
physician
One grass pollen tablet daily,
dissolves immediately under
the tongue.
Perennial intake.
Allergy
Therapeutics
Oralvac Compact Perennial start possible (Classical) Updosing at home over
10 days (bottle 1 to 3)
Dosing with a pump:
Daily 3 pumps of bottle 3,
minimum of 1–2 minutes before
swallowing
or Updosing on 1st day under
guidance of physician (bottle 3)
HAL Allergy Sublivac Perennial start possible Updosing at home over 5 days 5 drops daily, minimum of 1
minute, preferably 2–3 minutes
before swallowing
Laboratorios LETI TOL forte Preseasonal perennial Updosing at home. Maintenance
dose reached in 2 days. Single
concentration.
Dosing with a pump 2
pumps daily
Lofarma LAIS Sublingual
drops
Pre/coseasonal or perennial
therapy
Updosing at home over 4 days 6 drops daily for 120 days
minimum (pre/coseasonal
treatment) or 6 drops twice per
week (perennial treatment),
Sublingual intake minimum of 1–2
minutes before swallowing
Lofarma LAIS sublingual
tablets
Pre/coseasonal or perennial
therapy
Updosing at home over 4 days 1 tablet daily for 120 days
minimum (pre/coseasonal
treatment) or 2 tablets per week
(perennial treatment) tablet
dissolved under the tongue over a
minimum of 1 minute
ROXALL SULGEN Spray Perennial start possible (also
coseasonal)
Direct start with the maintenance
dose at home (no updosing
necessary)
2 spray doses daily, perlingual 2
minutes before swallowing
Stallergènes Staloral Preseasonal or coseasonal start,
therapy interruption after season,
optional perennial therapy
(Classical) Updosing at home over
11 days or Updosing on 1st day
under guidance of physician
(‘ultra-rush’)
8 pumps of bottle with highest
concentration daily or optionally 4
pumps daily in perennial therapy
Stallergènes Oralair Preseasonal start (recommended 4
months before pollen season),
coseasonal treatment, and then
therapy interruption after season
Updosing at home over 3 days One tablet (5-grass extract),
dissolving over a minimum of
2 minutes
*Modified with permission from [308,309].
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studies should be taken into account.
In contrast, less encouraging data are coming from the
SLIT European market. Two recent studies showed a
significant decrease of prescription renewal rates overtime [263,264]. According to these data, only 51% of pa-
tients in Germany and 30% in Italy stay on SLIT longer
than 2 years. In another analysis from the German mar-
ket the adherence to SLIT was even lower with only 16%
after three years of SLIT [316]. A recently published
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confirmed a low rate of adherence for both routes of ad-
ministration, even if higher for SCIT [317].
Factors affecting the adherence rate are important to
consider. The cost is one of the most relevant, and this
is clearly noticeable when comparing the sales of SLIT
where the treatment is reimbursed or is paid entirely out
of pocket by the patients [263]. Another important issue
to consider is patient education and information about
the clinical and immunologic benefit of specific AIT. Re-
cently, a small study reported a significantly higher rate
of adherence in patients who underwent short educa-
tional training than in a group that received only the in-
structions about SLIT administration [318]. In addition,
because SLIT is self-managed at home without direct
supervision, regular follow-up is mandatory. Vita and
co-workers reported a relationship between the number
of follow-up visits and the adherence to treatment [270].
In fact, the number of patients who withdrew from
treatment was significantly lower in the group of pa-
tients who received 3 visits/year than in the group of
patients who were seen at longer intervals. In another
study, acceptable adherence was achieved by the use of
an electronic device to remind patients to use SLIT
regularly over a 10-week period [319].
However, the cost/benefit ratio of such an approach in
the long term has to be confirmed. Reasons for poor ad-
herence to SLIT have been addressed in a survey carried
out among Italian allergists [265]: in addition to the need
for education and regular follow-up, the survey highlights
issues such as the tolerability and the treatment schedule.
Tolerability plays a pivotal role. Adverse events, mostly
local reactions, account for at least one-fourth of all drop-
outs in clinical trials and the rate is likely to be even higher
in real-life setting [320]. In fact severity, persistence or
simply poor awareness of local reactions may increase the
risk of treatment discontinuation, despite its efficacy. Even
the perception of allergen-specific immunotherapy among
GPs can be relevant to the adherence to SLIT: In a differ-
ent Italian survey, an 11-item questionnaire on AIT was
emailed to 200 GPs. Although the attitude towards this
therapy was generally favorable, fewer than 50% of GPs
were aware that international guidelines include SLIT as a
treatment option and provide suggestions for its use [210].
In conclusion, it seems that there is room for improv-
ing compliance by systematically addressing it and its
determinants and by putting more effort into educating
patients, GPs, and specialists.
Chapter 13: Perspectives & new approaches
 Recombinant allergens can be considered the
promising future of allergen immunotherapy (AIT).
They are currently used in clinical practice foradvanced allergy diagnosis and will possibly be used
in the future for AIT.
 After the patent expires on a biological therapeutic
product, similar products may emerge on the
market. These products are not generics, but are
rather defined as “biosimilars”. It will be critical to
have AIT products in the category of biosimilars to
preserve the quality of the treatments.
 Some sublingual immunotherapy (SLIT)
preparations include adjuvants with the aim of
amplifying the therapeutic effect by modulating the
immune response or/and further improving the
safety profile.
 Validity of single products should be reported in
publications in order to avoid generalized and
misleading judgments about AIT and to help
regulatory authorities in evaluating specific products
and clinicians in choosing scientifically supported
immunotherapy products in their practices.
Recombinant allergens
Modern technology has enabled the synthesis of recom-
binant proteins whose main advantages are their fully
characterized physical, chemical, and immunologic prop-
erties. It has become possible to produce well-defined
recombinant and synthetic allergy vaccines that can spe-
cifically target the mechanisms of the allergic disease
[321]. These can be considered the promising future of
AIT that will lead to personalized allergen immunother-
apy. In accordance with the new regulatory framework,
it is likely that the clinical development will be as recently
proposed by Cromwell [322]: “Personalized or patient-
tailored immunotherapy is still a very distant prospect, but
the first recombinant products based on single allergens or
defined mixtures could reach the market within the next
5 years.”
A more successful utilization of recombinant allergens
is already present in clinical practice for advanced allergy
diagnosis.
Biosimilars
After the patent expires on a biological therapeutic prod-
uct, similar products may emerge on the market. These
products are not generics, but are rather defined as “biosi-
milars” by the major regulatory authorities worldwide
[323]. One of the major differences between “generic” and
“biosimilar” is that biosimilars must undergo clinical de-
velopment for registration, including phase 3 studies, just
as in the case of the parental drug. The process of registra-
tion of AIT products started just a few years ago in many
countries.
Although the patent expiration is not an immediate
problem, it is critical to have AIT products (which are
biological and biotechnological products) in the category
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provided to allergic patients. In fact, biosimilars imply
that specific research, clinical monitoring, and pharma-
covigilance have occurred to produce a safe and appro-
priate use of these products.
Adjuvants and modified allergens
Some SLIT preparations include adjuvants with the aim
of amplifying the therapeutic effect by modulating the
immune response or of further improving the safety pro-
file. Adjuvants are substances that have the potential to
enhance the immunogenicity of antigens or allergens
and have largely been investigated for injected allergen
immunotherapy. Oral dendritic cells may be the ideal
target cells for adjuvanted SLIT, which could enhance
the tolerance mediated by these cells and mimic the nat-
ural contact of the individual’s immune system to aller-
gens [324].
Probiotics have been investigated as adjuvants for SLIT
in mouse models and have resulted in enhanced induction
of tolerance [325,326]. Another approach investigated the
use of detoxified bacterial toxins or carbohydrate polymers
adjuvanted to allergens as “microparticles” and mucoadhe-
sive particles [324,327-329]. Encouraging preliminary clin-
ical results in humans come from the first phase 1/2,
dose-ranging, placebo-controlled clinical trial with mono-
phosphoryl lipid A–adjuvanted SLIT [16]. The specific
immunological mechanisms underlying the therapeutic
potential of adjuvants and vector systems will be further
investigated in upcoming trials.
Chemically modified allergen preparations suitable for
sublingual administration have been obtained by carba-
mylation of the native allergen in order to maintain its
molecular dimension [330]. These preparations have
shown clinical efficacy and immunological effect in clin-
ical trials [331,332]. Carbamylated allergoids have the
advantage of reduced IgE-binding activity, which im-
proves the safety profile, and enhanced bioavailability, as
observed in pharmacokinetic studies [333].
These amplified features of SLIT products using adju-
vants and modified allergens suggest that fine-tuning of
doses and evaluation of the dose response is specifically
required with respect to traditional SLIT preparations.
Validity of single products
Meta-analyses have confirmed the effectiveness and safety
of SLIT [1,185,334-336]. Nonetheless, they evaluated the
available trials without considering differences between
products, preparations, dosages, schedules, and sometimes
allergens. Some scientists have called for AIT clinical trial
publications to specify the specific brand name of the
immunotherapy product used [337] for both positive
and negative results. This is crucial to avoid generalized
and misleading judgments about AIT and could helpregulatory authorities to evaluate specific products and
clinicians to choose scientifically supported allergen im-
munotherapy products in their practices.
Chapter 14: Raising public awareness about
sublingual immunotherapy
 Allergen immunotherapy (AIT) is effective in
alleviating allergy symptoms to a similar or even
greater extent than pharmacological treatments for
both asthma and allergic rhinitis; nonetheless,
awareness about AIT is still poor.
 Strategies to increase the awareness of AIT include
the following:
○ Patient associations should partner with medical
associations.
○ Collaboration between primary care physicians
and allergists is essential.
○ Proper educational programs should be designed
to increase knowledge about AIT.
○ Allergic diseases and AIT are still under-
recognized or not recognized by regulatory au-
thorities in many countries, although the num-
bers of allergic patients is increasing.
○ Harmonization among the regulations of
different countries is needed.
○ Scientific societies should partner, at any level,
to provide advice and promote this process.
○ Advocacy and education of government policy
makers will be crucial to secure more resources
for research on immunotherapy and similar
preventative strategies.Allergen immunotherapy (AIT) is effective in alleviat-
ing allergy symptoms to a similar or even greater extent
than pharmacological treatments for both asthma and
allergic rhinitis; it also has long-lasting effects that persist
after the treatment is discontinued. Moreover, immuno-
therapy has been shown to prevent the progression of
allergic diseases and to reduce the development of comor-
bidities and new sensitizations. Therefore, immunotherapy
is currently the only medical intervention that could
potentially alter the natural course of allergic diseases.
Better-standardized extracts and improved techniques and
routes of administration, like the introduction of sublin-
gual immunotherapy (SLIT), have further enhanced the
use of this treatment strategy. Increased awareness and
appropriate knowledge of immunotherapy amongst pa-
tients and policy makers is essential for better accessibility,
affordability, and sustainability of immunotherapy as a
treatment for all eligible patients.
Patients receiving immunotherapy frequently have poor
knowledge and unfounded expectations of various import-
ant aspects of their treatment. However, dissemination
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knowledge is crucial for better compliance and effective-
ness of immunotherapy [181]. About a decade ago, a
survey-based study documented that 39% of patients
expected complete recovery from their allergies, 20% of
patients had no idea about the timing of anticipated
improvement, and 18% expected improvement to occur
within days. Furthermore, 60% of patients were unaware
of any specified appropriate treatment duration, 33% con-
sidered immunotherapy to be without side effects, and
only 3.3% of patients correctly identified all of the aller-
gens to which they were undergoing desensitization [338].
A more recent, cross-sectional, Italian multicenter survey
in a large cohort treated with subcutaneous immunother-
apy (SCIT) or SLIT found that, despite some gaps and
misconceptions, the majority of patients had an adequate
level of knowledge, perception, expectations, and satisfac-
tion about AIT that was similar to the level of results ex-
pected by physicians [339]. In particular, most patients
acquired their knowledge of AIT from their physician and
perceived AIT to be safe and easy to integrate into a daily
routine. The main motivations for the use of AIT were its
potential effect to alter the natural course of the disease,
the reduced need for anti-allergy drugs, or dissatisfaction
with current pharmacotherapy. Of note, SLIT was fre-
quently considered easy to take and without side effects.
Consistent efforts to improve the awareness among the
lay public and patients at a global level will be crucial
for increasing patients’ knowledge about AIT, improving
their compliance, and promoting the success of this
therapeutic modality.
Recently, several societies have moved forward to in-
crease the awareness of AIT amongst patients, including
the World Allergy Organization and the European Acad-
emy of Allergy and Clinical Immunology [340,341] and
expert groups [181] focused on AIT awareness and its
implementation.
Major problematic issues that were identified by these
organizations included the following:
 Underappreciation of the science supporting AIT.
 Increased complexity of and time needed to perform
appropriate AIT studies, as compared with clinical
trials of drugs.
 Absence of reimbursement for AIT in many
countries.
 Limited availability of resources for AIT research
and promotion.Strategies to increase the awareness of AIT
Efforts by patient organizations, general practitioners,
non-allergist health care professionals, and pharmacists
will be needed to increase the awareness of AIT amongallergic patients. Campaigns should be targeted to pa-
tients as well as to policy makers.
The following can contribute to increasing awareness
of AIT:
 Patient associations should partner with medical
associations to help in disseminating knowledge and
awareness of allergy diagnosis.
 Collaboration between primary care physicians and
allergists is essential. Proper documentation and
instructions from the prescribing allergist’s office as
well as forms designed for complete and accurate
documentation of therapy are vital components of
safe administration.
 Proper educational programs should be designed to
increase knowledge about AIT within the
community.
 Although allergic diseases and AIT are under
consideration by regulatory authorities in many
countries, they are still under-recognized or not
recognized at all in many other countries with
increasing numbers of allergic patients.
 For better, uniform practice and introduction of
immunotherapy, harmonization among the
regulations of different countries is needed.
Scientific societies should partner, at any level, to
provide advice and promote this process.
 Advocacy and education of government policy
makers will be crucial to secure more resources for
research on immunotherapy and similar
preventative strategies.
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